Maria Alma Rodriguez

Peer-Reviewed Articles

1. Strati, P, Feng, L, Westin, JR, Nair, R, Fayad, LE, Rodriguez, MA, Chihara, D, Malpica Castillo, LE, Henderson, J, Gallardo, M, Rivera, M, Wang, I, Bolshakova, A, Radko, A, Kurtz, DM, Alig, S, Flowers, CR, Alizadeh, AA, Neelapu, SS. Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40775236.
2. Akkad, N, Feng, L, Westin, JR, Hagemeister, FB, Lee, HJ, Fayad, LE, Ahmed, S, Nair, R, Rodriguez, MA, Strati, P, Chihara, D, Flowers, CR, Claret, LC, Ibanez, K, Wang, L, Fowler, N, Henderson, J, Davis, RE, Neelapu, SS, Green, M, Nastoupil, L. A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood Advances 9(17):4396-4404, 2025. e-Pub 2025. PMID: 40517417.
3. Chihara, D, Steiner, RE, Nair, R, Feng, L, Ahmed, S, Strati, P, Malpica Castillo, LE, Griffith, D, Mathew, SA, Montinez, W, Masand, G, Samaniego, F, Rodriguez, MA, Hagemeister, FB, Fayad, LE, Iyer, SP, Nastoupil, L, Neelapu, SS, Flowers, CR, Westin, JR. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Advances 9(7):1485-1491, 2025. e-Pub 2025. PMID: 39908461.
4. Pinnix, CC, Dabaja, BS, Gunther, J, Fang, PQ, Wu, SY, Nastoupil, L, Strati, P, Nair, R, Ahmed, S, Steiner, RE, Westin, JR, Neelapu, SS, Rodriguez, MA, Lee, HJ, Wang, L, Flowers, CR, Feng, L, Esmaeli, B. Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma. JAMA Oncology 10(9):1195-1203, 2024. e-Pub 2024. PMID: 38990564.
5. Gunther, J, Xu, J, Bhutani, M, Strati, P, Fang, PQ, Wu, SY, Dabaja, BS, Dong, W, Bhosale, PR, Flowers, CR, Nair, R, Malpica Castillo, LE, Fayad, LE, Iyer, S, Parmer, S, Wang, ML, Lee, HJ, Samaniego, F, Westin, JR, Ahmed, S, Nze, CC, Jain, P, Neelapu, SS, Rodriguez, MA, Chihara, D, Nastoupil, L, Pinnix, CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma. The Lancet Haematology 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
6. Olguín JE, Corano-Arredondo E, Hernández-Gómez V, Rivera-Montoya I, Rodríguez MA, Medina-Andrade I, Arendse B, Brombacher F, Terrazas LI. A Myeloid-Specific Lack of IL-4Rα Prevents the Development of Alternatively Activated Macrophages and Enhances Immunity to Experimental Cysticercosis. Pathogens 13(2), 2024. e-Pub 2024. PMID: 38392907.
7. Cuellar P, Castañeda-Ortiz EJ, Rosales-Zarza C, Martínez-Rodríguez CE, Canela-Pérez I, Rodríguez MA, Valdés J, Azuara-Liceaga E. Genome-Wide Classification of Myb Domain-Containing Protein Families in Entamoeba invadens. Genes (Basel) 15(2), 2024. e-Pub 2024. PMID: 38397191.
8. Escalona Hernández V, Padilla-Martínez II, García RAV, Rodríguez MAV, Hernández-Ortiz OJ. Synthesis, and evaluation of photophysical properties of a potential DPP-derived photosensitizer for photodynamic therapy with D-A-D architecture. J Mater Sci Mater Med 35(1):11, 2024. e-Pub 2024. PMID: 38300359.
9. Rstakyan V, Mkhitaryan L, Baghdasaryan L, Ghaltaghchyan T, Karabekian Z, Sevoyan G, Aghayan M, Rodríguez MA. Stereolithography of ceramic scaffolds for bone tissue regeneration: Influence of hydroxyapatite/silica ratio on mechanical properties. J Mech Behav Biomed Mater 152:106421. e-Pub 2024. PMID: 38280269.
10. Rodríguez MA, Fernández LA, Díaz ML, Gallo CA, Corona M, Evans JD, Reynaldi FJ. Bacterial diversity using metagenomics of 16s rDNA in water kefir, an innovative source of probiotics for bee nutrition. Rev Argent Microbiol. e-Pub 2024. PMID: 38272730.
11. MÁ R, Crespo I, Guerra B, Del Valle M, Olmedillas H. Tailored Exercise Prescription According to Pharmacokinetic Compatibility: A New Horizon in Precision Medicine?. Curr Sports Med Rep 23(1):4-6, 2024. e-Pub 2024. PMID: 38180069.
12. Rodríguez MA, Echevarría M, Perdomo L, Gómez-Chiari M, García S, Prats P, Serra B, Albaiges G. Prevalence of corpus callosum pathology in an unselected population. Should assessment of the corpus callosum be included in the routine 20 weeks scan?. Prenat Diagn. e-Pub 2024. PMID: 38161311.
13. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204(1):e11-e16, 2024. e-Pub 2024. PMID: 37822075.
14. Leiva K, Trinidad A, Gonzalez I, Espinosa A, Zwick T, Levine JE, Rodriguez MA, Lev-Tov H, Wu W, Kirsner RS, Godavarty A. Development of a Tissue Oxygenation Flow-Based Index Toward Discerning the Healing Status in Diabetic Foot Ulcers. Adv Wound Care (New Rochelle) 13(1):22-33, 2024. e-Pub 2024. PMID: 37060195.
15. Rodriguez MA, Hooker RS, Puckett KK, Kozikowski A. Demographics of Physician Associates (PAs) in Obstetrics and Gynecology: Where They Work and How They Compare to Other PAs. Obstet Gynecol Int 2024:3057597, 2024. e-Pub 2024. PMID: 38419828.
16. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
17. González JE, Rodríguez MA, Caballero E, Pardo A, Marco S, Farré R. Open-source, low-cost App-driven Internet of Things approach to facilitate respiratory oscillometry at home and in developing countries. Pulmonology. e-Pub 2023. PMID: 37968180.
18. Chen L, Young MT, Rodriguez MA, Kietzman K. Immigrants' Enforcement Experiences and Concern about Accessing Public Benefits or Services. J Immigr Minor Health 25(5):1077-1084, 2023. e-Pub 2023. PMID: 36859637.
19. Dedhia PH, Sivakumar H, Rodriguez MA, Nairon KG, Zent JM, Zheng X, Jones K, Popova LV, Leight JL, Skardal A. A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity. Sci Rep 13(1):15508, 2023. e-Pub 2023. PMID: 37726363.
20. Avila Leon JL, Rivero CR, Guerrero L, Alviar JD, Rodríguez MA, Arocha AM, Pineda GG. Immediate results of the use of split-thickness skin autografts with and without acellular dermal matrix in patients with burns, a comparative study in a Colombian population. J Burn Care Res. e-Pub 2023. PMID: 37668065.
21. Cuevas E, Rodríguez A, Perez M, Murillo-Olmos J, Morales-Castañeda B, Alejo-Reyes A, Sarkar R. Optimal evaluation of re-opening policies for COVID-19 through the use of metaheuristic schemes. Appl Math Model 121:506-523, 2023. e-Pub 2023. PMID: 37234701.
22. MÁ R, Garcia-Segura LM, Cabezas R, Torrente D, Capani F, Gonzalez J, Barreto G. Corrigendum to "Tibolone protects T98G cells from glucose deprivation" [J. Steroid Biochem. Mol. Biol. 144 (2014) 294-303]. J Steroid Biochem Mol Biol 232:106292, 2023. e-Pub 2023. PMID: 36966021.
23. Sanft T, Day A, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Demark-Wahnefried W, Dickinson K, Fairman NP, Felciano J, Flores TF, Friedman DL, Gabel NM, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Koura D, Lee K, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Peterson L, Pirl W, Porpiglia A, Rodriguez MA, Schapira L, Schwartz AL, Smith S, Tevaarwerk A, Yang E, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines® Insights: Survivorship, Version 1.2023. J Natl Compr Canc Netw 21(8):792-803, 2023. e-Pub 2023. PMID: 37549906.
24. Dosta P, Cryer AM, Dion MZ, Shiraishi T, Langston SP, Lok D, Wang J, Harrison S, Hatten T, Ganno ML, Appleman VA, Taboada GM, Puigmal N, Ferber S, Kalash S, Prado M, Rodríguez AL, Kamoun WS, Abu-Yousif AO, Artzi N. Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nat Nanotechnol. e-Pub 2023. PMID: 37443252.
25. Zhukovsky DS, Soliman P, Liu D, Meyer M, Haider A, Heung Y, Gaeta S, Lu K, Stepan K, Stanton P, Rodriguez A, Bruera E. Patient Engagement With Early Stage Advance Care Planning at a Comprehensive Cancer Center. Oncologist 28(6):542-550, 2023. e-Pub 2023. PMID: 36848260.
26. Cherng, HJ, Alig, S, Oki, Y, Nastoupil, L, Fayad, LE, Neelapu, SS, Turturro, F, Hagemeister, FB, Craig, AF, Macaulay, CW, Rodriguez, MA, Lee, HJ, McDonnell, TJ, Flowers, CR, Vega Vazquez, F, Green, M, Feng, L, Kurtz, DM, Alizadeh, AA, Davis, RE, Westin, JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances 7(7):1137-1145, 2023. e-Pub 2023. PMID: 36375046.
27. Lopez-Olivo MA, James J, James J, Krause KJ, Roth M, Palos GR, Ma H, Rodriguez A, Gilmore K, Cinciripini P, Suarez-Almazor ME. A systematic review and meta-analysis of e-cigarette use among cancer survivors. J Cancer Surviv. e-Pub 2023. PMID: 36952212.
28. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2023. PMID: 35952327.
29. Cherng, HJ, Xu, G, Feng, L, Steiner, RE, Fayad, LE, Strati, P, Nair, R, Nastoupil, L, Lee, HJ, Neelapu, SS, Flowers, CR, Rodriguez, MA, Wang, L, Hagemeister, FB, Pinnix, CC, Ramdial, JL, Srour, S, Nieto, Y, Rezvani, K, Champlin, RE, Kebriaei, P, Westin, JR, Macapinlac, HA, Shpall, E, Ahmed, S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. British Journal of Haematology 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
30. Rodriguez MA, Hooker RS. Procedures by Physician Associates in Obstetrics and Gynecology. Womens Health Rep (New Rochelle) 4(1):536-543, 2023. e-Pub 2023. PMID: 38023373.
31. Dosta P, Puigmal N, Cryer AM, Rodríguez AL, Scott E, Weissleder R, Miller MA, Artzi N. Polymeric microneedles enable simultaneous delivery of cancer immunomodulatory drugs and detection of skin biomarkers. Theranostics 13(1):1-15, 2023. e-Pub 2023. PMID: 36593949.
32. Tu H, McQuade JL, Davies MA, Huang M, Xie K, Ye Y, Chow WH, Rodriguez A, Wu X. Body mass index and survival after cancer diagnosis: A pan-cancer cohort study of 114 430 patients with cancer. Innovation (Camb) 3(6):100344, 2022. e-Pub 2022. PMID: 36353671.
33. Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, Armenian S, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines® Insights: Survivorship, Version 1.2022. J Natl Compr Canc Netw 20(10):1080-1090, 2022. e-Pub 2022. PMID: 36240847.
34. Rodríguez A, Cuevas E, Zaldivar D, Morales-Castañeda B, Sarkar R, Houssein EH. An agent-based transmission model of COVID-19 for re-opening policy design. Comput Biol Med 148:105847, 2022. e-Pub 2022. PMID: 35932728.
35. Cherng, HJ, Sun, R, Sugg, B, Irwin, R, Yang, H, Le, CC, Deng, Q, Fayad, LE, Fowler, N, Parmar, S, Steiner, RE, Hagemeister, FB, Nair, R, Lee, HJ, Rodriguez, MA, Samaniego, F, Iyer, SP, Flowers, CR, Wang, L, Nastoupil, L, Neelapu, SS, Ahmed, S, Strati, P, Green, M, Westin, JR. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
36. Shbib Dabaja, B, Boyce-Fappiano, DR, Dong, W, Damron, EP, Fang, PQ, Gunther, J, Rodriguez, MA, Strati, P, Steiner, RE, Nair, R, Lee, H, Abou Yehia, Z, Shihadeh, F, Pinnix, CC, Ng, A. Second malignancies in patients with Hodgkin's Lymphoma. Clinical and Translational Radiation Oncology 35:64-69, 2022. e-Pub 2022. PMID: 35601797.
37. Marques-Piubelli, ML, Parra Cuentas, ER, Feng, L, Solis Soto, LM, Gallardo, M, Gouni, S, Samaniego, F, Noorani, M, Hagemeister, FB, Westin, JR, Lee, HJ, Rodriguez, MA, Neelapu, SS, Gunther, J, Fowler, N, Flowers, CR, Wistuba, II, Nastoupil, L, Vega Vazquez, F, Strati, P. SIRPa1 macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Advances 6(11):3286-3293, 2022. e-Pub 2022. PMID: 35359004.
38. Rodriguez, MA. Vaccinations for Patients With Cancer and Cancer Survivors. JNCCN Journal of the National Comprehensive Cancer Network 20(5.5):607-610, 2022. e-Pub 2022.
39. Cherng, HJ, Chuang, HH, Steiner, RE, Fayad, LE, Strati, P, Nair, R, Hagemeister, FB, Nastoupil, L, Lee, HJ, Neelapu, SS, Flowers, CR, Samaniego, F, Rodriguez, MA, Macapinlac, HA, Feng, L, Westin, JR. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leukemia and Lymphoma 63(1):74-83, 2022. e-Pub 2022. PMID: 34435552.
40. H-JJ C, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 63(1):74-83, 2022. e-Pub 2022.
41. Palos, Guadalupe R, Gilmore, Ramsey K, Chapman, Hansberry P, Rodriguez, Alma M. Implementation of ePROs in the care of long-term cancer survivors. Journal of Clinical Oncology 39:334-334, 2021. e-Pub 2021.
42. Alfano CM, Suarez-Almazor M, Rodriguez MA, Palos GR, Gilmore KR. Innovating the Personalization of Stratified Survivorship Care Pathways: Using a Cancer Data Ecosystem to Improve Care Access, Outcomes, Efficiency, and Costs. J Natl Cancer Inst Monogr 2021(57):3-9, 2021. e-Pub 2021. PMID: 34478510.
43. Rodriguez MA, Suarez-Almazor M, R Palos G. Guest Editors' Introduction. J Natl Cancer Inst Monogr 2021(57):1-2, 2021. e-Pub 2021. PMID: 34478506.
44. Gilmore KR, Rodriguez MA. Identifying Optimal Program Models and Clinical Tools for Follow-Up Care. J Natl Cancer Inst Monogr 2021(57):18-22, 2021. e-Pub 2021. PMID: 34478511.
45. Greenbaum, U, Strati, P, Saliba, RM, Torres, J, Rondon, G, Nieto, Y, Hosing, C, Srour, SA, Westin, J, Fayad, LE, Lee, HJ, Iyer, SP, Nair, R, Nastoupil, LJ, Parmar, S, Rodriguez, MA, Samaniego, F, Steiner, RE, Wang, M, Pinnix, CC, Flowers, CR, Tummala, S, Ramdial, JL, Yalniz, FF, Hawkins, M, Rezvani, K, Champlin, RE, Shpall, EJ, Neelapu, SS, Kebriaei, P, Ahmed, S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Advances 5(14):2799-2806, 2021. e-Pub 2021.
46. Tevaarwerk A, Denlinger CS, Sanft T, Ansbaugh SM, Armenian S, Baker KS, Broderick G, Day A, Demark-Wahnefried W, Dickinson K, Friedman DL, Ganz P, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Zee P, McMillian NR, Freedman-Cass DA. Survivorship, Version 1.2021. J Natl Compr Canc Netw 19(6):676-685, 2021. e-Pub 2021. PMID: 34214969.
47. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1361-1369, 2021. e-Pub 2021. PMID: 33480830.
48. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil L, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang ML, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins M, Johnson N, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers C, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood. e-Pub 2021. PMID: 33534891.
49. Strati, P, Jain, P, Johnson, RJ, Forbes, S, Feng, L, Samaniego, F, Rodriguez, MA, Fayad, LE, Hagemeister, F, Westin, J, Wang, M, Neelapu, SS, Nastoupil, LJ, Fowler, NH. Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood Articles 137(8):1124-1129, 2021. e-Pub 2021.
50. Samaniego F, McLaughlin P, Neelapu SS, Feng L, Fanale M, Nastoupil L, Rodriguez MA, Pro B, Taylor E, Hagemeister FB, Fowler N. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leuk Lymphoma 62(1):58-67, 2021. e-Pub 2021. PMID: 32924687.
51. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. e-Pub 2019. PMID: 31036721.
52. Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F. Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. Br J Haematol 185(4):670-678, 2019. e-Pub 2019. PMID: 30820940.
53. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 41(5):1546, 2019. e-Pub 2019. PMID: 30990235.
54. Middleton LP, Thompson L, Starr-High E, Travis E, Kurtin D, Rodriguez MA, Dmitrovsky E. Getting New Clinical Faculty into the Fold — Fast. Physician Leadership Journal, 2018. e-Pub 2018.
55. Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(10):1216-1247, 2018. e-Pub 2018. PMID: 30323092.
56. Pierzynski JA, Ye Y, Lippman SM, Rodriguez MA, Wu X, Hildebrandt MAT. Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8(1):10640, 2018. e-Pub 2018. PMID: 30006595.
57. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 40(6):1335, 2018. e-Pub 2018. PMID: 29851218.
58. Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. e-Pub 2018. PMID: 29723393.
59. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
60. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys. e-Pub 2018. PMID: 29681481.
61. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2018. PMID: 29196178.
62. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLOS One (Public Library of Science) 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
63. Sano D, Nastoupil LJ, Fowler NH, Fayad L, Hagemeister FB, Lee HJ, Samaniego F, Wang M, Rodriguez MA, Iyer SP, Parmar S, Steiner R, Nair R, Adkins S, Arafat S, Rao A, Vallejo L, Hawkins M, Chen Y, Westin JR, Neelapu SS. Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma. Blood 132(96), 2018. e-Pub 2018.
64. Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(9):1140-1163, 2017. e-Pub 2017. PMID: 28874599.
65. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma:1-8. e-Pub 2017. PMID: 28792260.
66. Pinnix CC, Andraos TY, Dabaja B, Milgrom S, Smith G, Chihara D, Ng A, Fayad LE, Oki Y, Neelapu S, Westin J, Rodriguez MA, Nastoupil LJ. Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. Adv Radiat Oncol 2(3):370-380, 2017. e-Pub 2017. PMID: 29114605.
67. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck 39(6):1095-1100, 2017. e-Pub 2017. PMID: 28370694.
68. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad L, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. Blood 130(4). e-Pub 2017. PMID: 28522441.
69. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). Leuk Lymphoma:1-12. e-Pub 2017. PMID: 28482717.
70. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist 22(5):549-553, 2017. e-Pub 2017. PMID: 28408615.
71. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol 177(2):263-270, 2017. e-Pub 2017. PMID: 28340281.
72. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2017. PMID: 27983760.
73. Cheng L, DeJesus AY, Rodriguez MA. Using Laboratory Test Results at Hospital Admission to Predict Short-term Survival in Critically Ill Patients With Metastatic or Advanced Cancer. J Pain Symptom Manage. e-Pub 2017. PMID: 28062337.
74. Westin JR, Oki Y, Nastoupil L, Fayad L, Neelapu SS, Turturro F, Hagemeister FB, Rodriguez MA, Lee HJ, Young KH, McDonnell TJ, Ford RJ, Davis RE. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results. Blood 130(suppl 1):189, 2017. e-Pub 2017.
75. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
76. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol 175(2):290-299, 2016. e-Pub 2016. PMID: 27448187.
77. Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson MM, Zelenetz AD, Niland J, Friedberg JW, Winter JN. High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. J Natl Compr Canc Netw 14(10):1274-1281, 2016. e-Pub 2016. PMID: 27697981.
78. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. e-Pub 2016. PMID: 27378601.
79. Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Sanft T, Silverman P, Smith S, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines Insights: Survivorship, Version 1.2016. J Natl Compr Canc Netw 14(6):715-24, 2016. e-Pub 2016. PMID: 27283164.
80. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. e-Pub 2016. PMID: 27227654.
81. Crosby MA, Cheng L, DeJesus AY, Travis EL, Rodriguez MA. Provider and Patient Gender Influence on Timing of Do-Not-Resuscitate Orders in Hospitalized Patients with Cancer. J Palliat Med. e-Pub 2016. PMID: 27159269.
82. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. e-Pub 2016. PMID: 27091808.
83. Akhtari M, Reddy JP, Pinnix CC, Allen PK, Osborne EM, Gunther JR, Milgrom SA, Smith GL, Wogan CF, Fowler N, Rodriguez MA, Dabaja B. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leuk Lymphoma 57(1):34-8, 2016. e-Pub 2016. PMID: 25860237.
84. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 2016. e-Pub 2016. PMID: 26648336.
85. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. e-Pub 2016. PMID: 26802151.
86. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Medeiros LJ, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. Blood 128(22):4153, 2016. e-Pub 2016.
87. Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez A, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience. Blood 128(22):106, 2016. e-Pub 2016.
88. Hu B, Younes A, Claret L, Feng L, Westin JR, Fowler N, Neelapu S, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA, Oki Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Blood 128(22):1833, 2016. e-Pub 2016.
89. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 26795083.
90. Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Cunningham S, Zhao H, Hawk ET, Wagar E, Rodriguez A, Hamilton SR. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol. e-Pub 2015. PMID: 26686840.
91. Reddy JP, Akhtari M, Smith GL, Pinnix C, Osborne EM, Gunther JR, Allen PK, Yehia ZA, Fanale M, Rodriguez MA, Fowler N, Milgrom SA, Wogan CF, Dabaja BS. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clin Lymphoma Myeloma Leuk 15(11):664-670.e2, 2015. e-Pub 2015. PMID: 26321471.
92. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 2015. e-Pub 2015. PMID: 26260306.
93. Wagner-Johnston ND, Goy A, Rodriguez MA, Ehmann WC, Hamlin PA, Radford J, Thieblemont C, Suh C, Sweetenham J, Huang Y, Sullivan ST, Vandendries ER, Gisselbrecht C. A Phase 2 Study of Inotuzumab Ozogamicin and Rituximab, Followed by Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Leuk Lymphoma 56(10):1-27, 2015. e-Pub 2015. PMID: 25707288.
94. Palos GR, Lewis-Patterson P, Gilmore K, DeJesus Y, Rodriguez AM. Changing Nursing Practice in Survivorship Care With Clinical Decision Tools. Clin J Oncol Nurs 19(4):482-4, 488, 2015. e-Pub 2015. PMID: 26207716.
95. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 2015. e-Pub 2015. PMID: 25828695.
96. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol 169(5):689-93, 2015. e-Pub 2015. PMID: 25818067.
97. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys 92(1):122-9, 2015. e-Pub 2015. PMID: 25754633.
98. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of Radiation Pneumonitis in Patients Receiving Intensity-Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-82, 2015. e-Pub 2015. PMID: 25863764.
99. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated with Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 2015. e-Pub 2015. PMID: 25863759.
100. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label single arm phase II trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2015. PMID: 25445468.
101. Leal I, Engebretson J, Cohen L, Rodriguez A, Wangyal T, Lopez G, Chaoul A. Experiences of paradox: a qualitative analysis of living with cancer using a framework approach. Psychooncology 24(2):138-46, 2015. e-Pub 2015. PMID: 24831084.
102. Ahmed MA, Oki Y, Noorani M, Nastoupil L, Fayad LE, Hagemeister FB, Rodriguez A, Davis RE, Westin JR. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. Blood 126(23):3965, 2015. e-Pub 2015.
103. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood 126(23):2738, 2015. e-Pub 2015.
104. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood 126(23):3984, 2015. e-Pub 2015.
105. Sehgal L, Tamer K, Wang X, Mathur R, Berkova Z, Romaguera JE, Rodriguez A, Neelapu SS, Samaniego F. Tumor Microenvironment Regulates Survival of Mantle Cell Lymphoma Cells through Various Signaling Pathways. Blood 126(23):4775, 2015. e-Pub 2015.
106. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol 10:206, 2015. e-Pub 2015. PMID: 26407853.
107. Gallagher CM, Farroni JS, Moore JA, Nates JL, Rodriguez MA. The Misleading Vividness of a Physician Requesting Futile Treatment. Am J Bioeth 15(8):52-3, 2015. e-Pub 2015. PMID: 26225522.
108. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8:63, 2015. e-Pub 2015. PMID: 26048374.
109. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 126(23):1502, 2015. e-Pub 2015.
110. Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. e-Pub 2014. PMID: 25492236.
111. Haque W, Voong KR, Shihadeh F, Arzu I, Pinnix C, Mazloom A, Medeiros LJ, Romaguera J, Rodriguez A, Wang M, Allen P, Dabaja B. Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. Clin Lymphoma Myeloma Leuk 14(6):474-9, 2014. e-Pub 2014. PMID: 25108680.
112. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: screening for cancer and treatment effects, version 2.2014. J Natl Compr Canc Netw 12(11):1526-31, 2014. e-Pub 2014. PMID: 25361799.
113. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 12(10):1396-406, 2014. e-Pub 2014. PMID: 25313179.
114. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
115. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: healthy lifestyles, version 2.2014. J Natl Compr Canc Netw 12(9):1222-37, 2014. e-Pub 2014. PMID: 25190692.
116. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: immunizations and prevention of infections, version 2.2014. J Natl Compr Canc Netw 12(8):1098-111, 2014. e-Pub 2014. PMID: 25099442.
117. Palos GR, Zandstra F, Gilmore K, Russell L, Flores J, Rodriquez MA. Transforming cancer survivorship care through quality improvement initiatives. Clin J Oncol Nurs 18(4):468-70, 2014. e-Pub 2014. PMID: 25095303.
118. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. e-Pub 2014. PMID: 25039868.
119. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys 89(2):384-91, 2014. e-Pub 2014. PMID: 24721592.
120. Rodriguez MA, DeJesus AY, Cheng L. Use of Chemotherapy Within the Last 14 Days of Life in Patients Treated at a Comprehensive Cancer Center. JAMA Intern Med, 2014. e-Pub 2014.
121. Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, Lacasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. e-Pub 2014. PMID: 24706502.
122. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 2014. e-Pub 2014. PMID: 24386943.
123. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837-42, 2014. e-Pub 2014. PMID: 24264230.
124. Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol 163(4):487-95, 2013. e-Pub 2013. PMID: 24111533.
125. Palos GR, Tortorella FR, Stepen K, Rodriguez MA. A Multidisciplinary Team Approach to Improving Psychosocial Care in Patients With Cancer. Clin J Oncol Nurs 17(5):556-558, 2013. e-Pub 2013. PMID: 24080057.
126. Evens AM, Vanderplas A, Lacasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 119(20):3662-3671, 2013. e-Pub 2013. PMID: 23921646.
127. Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk Lymphoma 54(10):2155-62, 2013. e-Pub 2013. PMID: 23343180.
128. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective Phase II Study of Rituximab with Alternating Cycles of Hyper-CVAD and High-Dose Methotrexate with Cytarabine for Young Patients with High-Risk Diffuse Large B-Cell Lymphoma. Br J Haematol. e-Pub 2013. PMID: 24117234.
129. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 162(5):631-8, 2013. e-Pub 2013. PMID: 23802738.
130. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 122(4):499-506, 2013. e-Pub 2013. PMID: 23692856.
131. Armand P, Oki Y, Neuberg D, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, LaCasce A, Jacobsen E, Davids M, Jacobson C, Fisher D, Brown J, Fowler N, Rodriguez MA, Wallace M, Neelapu S, Rodig S, Younes A, Freedman A. Detection of CirculatingTumor DNA in Patients with Aggressive B-cell Non-Hodgkin Lymphoma. British Journal of Haematology, 2013. e-Pub 2013. PMID: 2379511.
132. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma. e-Pub 2013. PMID: 23488661.
133. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk 13(1):15-8, 2013. e-Pub 2013. PMID: 23137719.
134. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer 118(11):2944-51, 2012. e-Pub 2012. PMID: 22006274.
135. Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, LaCasce AS. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma 53(6):1113-6, 2012. e-Pub 2012. PMID: 22098406.
136. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A Randomized Trial of a Single-Dose Rasburicase Versus Five-Daily Doses in Patients at Risk for Tumor Lysis Syndrome. Annals of Oncology 23(6):1640-5, 2012. e-Pub 2012.
137. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
138. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 2012. e-Pub 2012. PMID: 22023528.
139. Lacasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 119(9):2093-9, 2012. e-Pub 2012. PMID: 22234679.
140. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma 53(1):50-6, 2012. e-Pub 2012. PMID: 21895545.
141. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, Bruera E, Buzdar A, Foxhall L, Hui D, Summers B, Rodriguez A, Dubois R, Shine KI. Ensuring quality cancer care: A follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in america. Cancer. e-Pub 2011. PMID: 22045610.
142. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer 117(14):3268-75, 2011. e-Pub 2011. PMID: 21264831.
143. Selvan MS, Subbian S, Cantor SB, Rodriguez A, Smith ML, Walsh GL. Ethics of transparency in research reports. Indian Journal of Medical Ethics VIII(1), 2011. e-Pub 2011.
144. Parker PA, Ross AC, Polansky MN, Palmer JL, Rodriguez MA, Baile WF. Communicating with Cancer Patients: What Areas do Physician Assistants Find Most Challenging?. J Cancer Educ 25(4):524-9, 2010. e-Pub 2010. PMID: 20383673.
145. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD Alternating with Rituximab, Methotrexate and Cytarabine for Untreated Aggressive Mantle Cell Lymphoma. British Journal of Haematology 151(1):47-53, 2010. e-Pub 2010.
146. Jones JA, Fayad LE, Elting LS, Rodriguez MA. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 51(9):1649-57, 2010. e-Pub 2010. PMID: 20807093.
147. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS. Benefit of Consolidative Radiation Therapy in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy. Journal of Clinical Oncology. e-Pub 2010.
148. Rodriguez MA, Tortorella F, St John C. Improving Psychosocial Care for Improved Health Outcomes. J Healthc Qual 32(32/4):3-13, 2010. e-Pub 2010. PMID: 20618566.
149. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 2010. e-Pub 2010. PMID: 20528872.
150. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez A, Samaniego F, McLaughlin PW, Hagemeister FB, Neelapu SS, Copeland AR, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II Study of Yttrium-90 (90Y)-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology 27(31):5213-8, 2009. e-Pub 2009.
151. Pawlik TM, Olver IN, Storm CD, and Rodriguez MA. Can Physicians Refuse Treatment to Patients Who Smoke?. Journal of Oncology Practice 5(5):250-251, 2009. e-Pub 2009.
152. Rodriguez MA, Pytlik R, Kozak T, Chhanabhai M, Gascoyne R, Lu B, Deitcher SR, Winter JN. Vincristine Sulfate Liposomes Injection (Marqibo) in Heavily Pretreated Patients with Refractory Aggressive non-Hodgkin Lymphoma: Report of the Pivotal Phase 2 Study. Cancer 115(15):3475-3482, 2009. e-Pub 2009. PMID: 19536896.
153. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro B. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20(6):1080-5, 2009. e-Pub 2009. PMID: 19237479.
154. Rodriguez MA, Storm CD, Burris, III HA. Medical Errors: Physician and Institutional Responsibilities. Journal of Oncology Practice 5(1), 2009. e-Pub 2009.
155. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 2008. e-Pub 2008. PMID: 18973182.
156. LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA, Czuczman MS, Millenson MM, Zelenetz AD, Weeks JC. Comparison of Referring and Final Pathology for Patients with Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network. Journal of Clinical Oncology 26(31):5107-5112, 2008. e-Pub 2008.
157. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Combination with Rituximab in Patients with Recurrent B-cell Non-Hodgkin Lymphoma. British Journal of Haematology, 2008. e-Pub 2008.
158. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 19(3):553-9, 2008. e-Pub 2008. PMID: 18083690.
159. Soriano AI, Thompson MA, Admirand JH, Fayad LE, Rodriguez MA, Romaguera JE, Hagemeister FB, Pro B. Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature. Am. J. Hematol, 2007. e-Pub 2007.
160. Slieper CF, Hyle LR, Rodriguez MA. Difficult discharge: lessons from the oncology setting. Am. J. Bioethics 7(3):31-2, 2007. e-Pub 2007.
161. Dang NH, Pro B, Hagemeister F, Samaniego F, Jones D, Samuels B, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Francesco T, Walter PL, Fayad L. Phase II Trial of Denileukin Diftitox for Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma. Br. J. Haemat 136(3):439-47, 2007. e-Pub 2007.
162. Russell NC, Hoelscher DM, Janszen L, Rodriguez MA. Dietary and weight changes after treatments for lymphoma. Nutr Cancer 57(2):168-76, 2007. e-Pub 2007. PMID: 17571950.
163. Thompson MA, Habra MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG, Rodriguez MA. Primary adrenal natural killer/T-cell nasal type lymphoma: First case report in adults. Am J Hematol, 2006. e-Pub 2006. PMID: 17094095.
164. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194:1394-7, 2006. e-Pub 2006. PMID: 17054068.
165. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47:1818-21, 2006. e-Pub 2006. PMID: 17064994.
166. Liu Q, Fayad L, Cabanillas F, Hagemeister F, Ayers G, hess M, Romaguera R, Rodriguez A, Tsimberidou A, Verstovsek S, Younes A, Pro B, Lee M, Ayala A, McLaughlin P. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 years of Treatment Experience at The University of Texas M. D. Anderson Cancer Center. J. Clin. Oncol 24, No. 10:1582-1589, 2006. e-Pub 2006.
167. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Erratum in Cancer 106(7):1641, 2006. e-Pub 2006.
168. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-5, 2006. e-Pub 2006. PMID: 16396772.
169. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106(1):120-7, 2006. e-Pub 2006.
170. Ha CS, Blanco AI, Tucker SL, Fayad LE, hess MA, Podoloff DA, Hagemeister F, Rodriguez MA. Comparison of F-FDG PET Scan with 67 Ga-citrate Scan for Imaging of diffuse Large B-cell Lymphoma/A Prospective Study. Int. J. Radiat. Oncol. Biol. Phys 66(3) Suppl):S499-S500, 2006. e-Pub 2006.
171. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. Journal of Clinical Oncology 23(28):7013-23, 2005. e-Pub 2005.
172. Ha CS, Cabanillas F, Lee MS, Tucker SL, McLaughlin P, Rodriguez MA, Younes A, Romaguera JE, Mesina O, Cox JD. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation (CLI) and Intensive Alternating Triple Chemotherapy (ATT) in the treatment of stage I-III follicular lyjphoma. Int. J. Radiat. Oncol. Biol. Phys 63(1):188-193, 2005. e-Pub 2005.
173. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104:345-53, 2005. e-Pub 2005. PMID: 15948158.
174. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippolity C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Gy A, Younes A, Champlin RE. Reduced-intensity Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen. Bone Marrow Transplantation 35(10):943-51, 2005. e-Pub 2005.
175. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-75, 2005. e-Pub 2005. PMID: 15613697.
176. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22:4095-102, 2004. e-Pub 2004. PMID: 15353540.
177. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10:5432-8, 2004. e-Pub 2004. PMID: 15328181.
178. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer 100:1186-9, 2004. e-Pub 2004. PMID: 15022285.
179. Cohen L, Warneke C, Fouladi RT, Rodriguez MA. Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma. Cancer 100(10):2253-2260, 2004. e-Pub 2004.
180. Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease. American Journal of Clinical Oncology Feb. 27 (1):73-80, 2004. e-Pub 2004.
181. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10:1513-8, 2003. e-Pub 2003. PMID: 12883733.
182. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jr, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98:310-4, 2003. e-Pub 2003. PMID: 12872350.
183. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 14:737-44, 2003. e-Pub 2003. PMID: 12702528.
184. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97:586-91, 2003. e-Pub 2003. PMID: 12548600.
185. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 55:36-43, 2003. e-Pub 2003. PMID: 12504034.
186. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100:4351-7, 2002. e-Pub 2002. PMID: 12393618.
187. Lee HK, Wilder RB, Jones D, Ha CS, Pro B, Rodriguez MA, Romaguera JE, Cabanillas F, Rodriguez J, Cox JD. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 43:1769-75, 2002. e-Pub 2002. PMID: 12685830.
188. Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park) 16:27-31, 2002. e-Pub 2002. PMID: 12199630.
189. Visco C, Medeiros LJ, Jones D, Smith T, Rodriguez MA, McLaughlin P, Romaguera J, Cabanillas F, Sarris AH. Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. Ann Oncol 13:1290-9, 2002. e-Pub 2002. PMID: 12181254.
190. Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 94:3083-8, 2002. e-Pub 2002. PMID: 12115338.
191. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, Mesina O, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McLaughlin P, Rodriguez MA, Romaguera J, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 20:1278-87, 2002. e-Pub 2002. PMID: 11870170.
192. Fayad LE, Romaguera J, Pro B, Younes A, Dang NH, Samaniego F, Garcia-Tejido P, Sarris A, Rodriguez MA, Hagemeister F, McLaughlin P, Goy A, cabanillas F, Rodriguez P. Primary Mediastinal Large B-Cell Lymphoma (PMLBL): Poor Prognosis in Patients with Extranodal Sites. Blood 98(11), 2001. e-Pub 2001.
193. Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 12(7):923-7, 2001. e-Pub 2001. PMID: 11521796.
194. Sarris AH, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Younes A, Mesina O, Cabanillas F, Medeiros LJ, Samuels B. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma. Oncology (Williston Park) 15(7 Suppl 8):53-6, 2001. e-Pub 2001. PMID: 11497233.
195. Wilder RB, Rodriguez MA, Tucker SL, Ha CS, Hess MA, Cabanillas FF, Cox JD. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys 50(3):743-9, 2001. e-Pub 2001. PMID: 11395243.
196. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, Cox JD. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91(12):2440-6, 2001. e-Pub 2001. PMID: 11413536.
197. Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera JE, Cabanillas F, Sarris AH. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?. Clin Lymphoma 2(1):40-6, 2001. e-Pub 2001. PMID: 11707869.
198. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma 41(5-6):535-44, 2001. e-Pub 2001. PMID: 11378571.
199. van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 27(4):397-404, 2001. e-Pub 2001. PMID: 11313669.
200. Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, Ha CS, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera J, Cox J, Cabanillas F. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol 19(2):398-405, 2001. e-Pub 2001. PMID: 11208831.
201. Wilder RB, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 49(1):17-22, 2001. e-Pub 2001. PMID: 11163493.
202. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 11(12):1551-6, 2000. e-Pub 2000. PMID: 11205462.
203. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 Suppl 12):37-41, 2000. e-Pub 2000. PMID: 11225999.
204. Schlembach PJ, Wilder RB, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys 48(4):1107-10, 2000. e-Pub 2000. PMID: 11072169.
205. Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma 39(3-4):291-9, 2000. e-Pub 2000. PMID: 11342309.
206. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Korbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, McLaughlin P, Cabanillas F, Champlin RE. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 26(6):615-20, 2000. e-Pub 2000. PMID: 11041566.
207. Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J, Cabanillas F. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 39(1-2):77-85, 2000. e-Pub 2000. PMID: 10975386.
208. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 11 Suppl 1:137-40, 2000. e-Pub 2000. PMID: 10707796.
209. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11(1):69-72, 2000. e-Pub 2000. PMID: 10690390.
210. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 35(3-4):317-24, 1999. e-Pub 1999. PMID: 10706456.
211. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 131(2):88-95, 1999. e-Pub 1999. PMID: 10419446.
212. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F, Hagemeister FB. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 93(11):3632-6, 1999. e-Pub 1999. PMID: 10339468.
213. Lopez-Guillermo A, Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 93(9):3081-7, 1999. e-Pub 1999. PMID: 10216105.
214. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 10(4):433-40, 1999. e-Pub 1999. PMID: 10370786.
215. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93(7):2202-7, 1999. e-Pub 1999. PMID: 10090928.
216. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez J, Preti A, Younes A, Sarris AH, Cabanillas F. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest New Drugs 17(2):187-92, 1999. e-Pub 1999. PMID: 10638491.
217. Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma 32(1-2):97-106, 1998. e-Pub 1998. PMID: 10037005.
218. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16(12):3803-9, 1998. e-Pub 1998. PMID: 9850025.
219. Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas F. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol 103(3):678-83, 1998. e-Pub 1998. PMID: 9858216.
220. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Hess MA, Tucker SL, Cabanillas F, Cox JD. Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997. Radiology 208(3):739-47, 1998. e-Pub 1998. PMID: 9722855.
221. Cabanillas F, Rodriguez-Diaz Pavon J, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera JE, Dong K, Moon T. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol 9(5):511-8, 1998. e-Pub 1998. PMID: 9653492.
222. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. The clinical significance of molecular response in indolent follicular lymphomas. Blood 91(8):2955-60, 1998. e-Pub 1998. PMID: 9531606.
223. Strom SS, Gu Y, Sigurdson AJ, Bailey NM, Amos CI, Spitz MR, Rodriguez MA, Liang JC. Chromosome breaks and sister chromatid exchange as predictors of second cancers in Hodgkin's disease. Leuk Lymphoma 28(5-6):561-6, 1998. e-Pub 1998. PMID: 9613986.
224. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91(4):1178-84, 1998. e-Pub 1998. PMID: 9454747.
225. Fuller LM, Mirza NQ, Palmer JL, Davis BR, Ha CS, Rodriguez MA, Hagemeister FB, Cabanillas F, McLaughlin P, Butler JJ, North LB, Martin RG. Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. Int J Radiat Oncol Biol Phys 40(2):377-86, 1998. e-Pub 1998. PMID: 9457824.
226. Romaguera JE, Rodriguez Diaz-Pavon J, Carias L, Bacher C, Hagemeister FB, McLaughlin P, Preti A, Rodriguez MA, Sarris AH, Younes A, Cabanillas F. Use of the International Prognostic Index and the tumor score to detect poor risk patients with primary mediastinal large B cell lymphoma: A study of 37 previously untreated patients. Leuk. Lymph 28(3-4):295-306, 1998. e-Pub 1998.
227. Sarris AH, Kliche KO, Peethambaram PP, Preti A, Jacklow C, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Fristshe H, Duvic M, Witzig T, Cabanillas F. (FFS) of Adult Hodgkin’s disease (HD). The Fourth International Symposium on Lymphoma 29(1):32, 1998. e-Pub 1998.
228. Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 16(1):63-9, 1998. e-Pub 1998. PMID: 9440724.
229. Meistrich ML, Wilson G, Mathur K, Fuller LM, Rodriguez MA, McLaughlin P, Romaguera JE, Cabanillas FF, Ha CS, Lipshultz LI, Hagemeister FB. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol 15(12):3488-95, 1997. e-Pub 1997. PMID: 9396402.
230. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD. Long-term outcome of treatment for Ann Arbor stage I Hodgkin’s disease patterns of failure, late toxicity and second malignancies. Int. J. Radiat. Oncol. Biol. Phys 39(3):609-316, 1997. e-Pub 1997.
231. Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 26(1-2):77-82, 1997. e-Pub 1997. PMID: 9250790.
232. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89(12):4514-20, 1997. e-Pub 1997. PMID: 9192775.
233. Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma correlation of clinical outcome and biologic features with three histologic variants. J. Clin. Oncol 15(4):1664-1671, 1997. e-Pub 1997.
234. Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol 96(2):328-32, 1997. e-Pub 1997. PMID: 9029021.
235. Rodriguez J, Romaguera J, McLaughlin P, Hagemeister F, Rodriguez MA, Cabanillas F. Dose intensity as a treatment related variable in aggressive non-Hodgkin’s lymphoma. Blood 90:267b, 1997. e-Pub 1997.
236. Younes A, Ayoub JP, Sarris A, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Hagemeister F, Bachier C, Preti A, Cabanillas F. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol 8 Suppl 1:129-31, 1997. e-Pub 1997. PMID: 9187446.
237. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Hess MA, Tucker SL, Cabanillas F, Cox JD. Radiotherapy and chemotherapy for stage I Hodgkin’s disease: The University of Texas M.D. Anderson Cancer Center Experience 1967-1997. Int. J. Radiat. Onc. Biol. Phys 39(3):609-616, 1997. e-Pub 1997.
238. Shipp MA, Ambinder RF, Appelbaum FR, Cabanillas F, Harris NJ, Herzig GP, Hoppe RT, Horning SJ, Pezner RD, Rodriguez MA, Vose JM, Yahalom J, Zelenetz AD. NCCN Preliminary non-Hodgkin’s Lymphoma Practice Guidelines. J. Clin. Oncol 11(11A):281-346, 1997. e-Pub 1997.
239. Younes A, Sarris A, Consoli U, Rodriguez A, McLaughlin P, Huh Y, Starry S, Cabanillas F, Andreeff M. A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results. Blood 87:1698-703, 1996. e-Pub 1996. PMID: 8634414.
240. Seymour JF, McLaughlin P, Fuller LM, Hagemeister FB, Hess M, Swan F, Romaguera J, Rodriguez MA, Besa P, Cox J, Cabanillas F. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol 7:157-63, 1996. e-Pub 1996. PMID: 8777172.
241. Younes A, Ayoub JP, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F, Jr, Romaguera JE, Martin J, Cabanillas F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 14:543-8, 1996. e-Pub 1996. PMID: 8636769.
242. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14:233-9, 1996. e-Pub 1996. PMID: 8558203.
243. Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 6:609-11, 1995. e-Pub 1995. PMID: 8573542.
244. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734-41, 1995. e-Pub 1995. PMID: 7602363.
245. Suki S, Swan F, Jr, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, McLaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma 18:87-92, 1995. e-Pub 1995. PMID: 8580834.
246. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 15:549-55, 1995. e-Pub 1995. PMID: 7655380.
247. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 13:583-7, 1995. e-Pub 1995. PMID: 7884419.
248. Moore DF, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F. Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study. Clin Oncol (R Coll Radiol) 7:300-3, 1995. e-Pub 1995. PMID: 8580055.
249. Fuller LM, Krasin MJ, Velasquez WS, Allen PK, McLaughlin P, Rodriguez MA, Hagemeister FB, Swan F, Jr, Cabanillas F, Palmer JL, et al. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys 31:3-11, 1995. e-Pub 1995. PMID: 7527799.
250. Rodriguez J, Pugh WC, Romaguera JE, Luthra R, Hagemeister FB, McLaughlin P, Rodriguez MA, Swan F, Cabanillas F. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol 5:847-9, 1994. e-Pub 1994. PMID: 7848887.
251. Younes A, Jendiroba D, Engel H, Escudier S, Katz R, Rodriguez MA, Hill D, Cabanillas F, Andreeff M. High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement. Cancer Genet Cytogenet 77:39-44, 1994. e-Pub 1994. PMID: 7923081.
252. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169-76, 1994. e-Pub 1994. PMID: 8201379.
253. Velasquez WS, McLaughlin P, Fuller LM, Allen PK, Tucker SL, Swan F, Jr, Rodriguez MA, Hagemeister FB, Cabanillas FF. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer 73:2408-16, 1994. e-Pub 1994. PMID: 7513251.
254. Cabanillas F, Rodriguez MA. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas. Semin Hematol 31:30, 1994. e-Pub 1994. PMID: 8073305.
255. Hagemeister FB, Purugganan R, Fuller L, McLaughlin P, Swan F, Jr, Romaguera J, Rodriguez M, Cabanillas F. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol 31:36-43, 1994. e-Pub 1994. PMID: 8073308.
256. Younes A, Pugh W, Goodacre A, Katz R, Rodriguez MA, Hill D, Cabanillas F, Andreeff M. Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma. Genes Chromosomes Cancer 9:161-7, 1994. e-Pub 1994. PMID: 7515657.
257. McLaughlin P, Hagemeister FB, Swan F, Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-9, 1994. e-Pub 1994. PMID: 8120556.
258. Hagemeister FB, Purugganan R, Podoloff DA, Hess M, Rodriguez MA, McLaughlin P, Swan F, Jr, Romaguera JE, Cabanillas F. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol 5 Suppl 2:59-63, 1994. e-Pub 1994. PMID: 8204521.
259. Hagemeister FB, Khetan R, Allen P, McLaughlin P, Rodriguez MA, Swan F, Jr, Romaguera JE, Cabanillas F. Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol 5 Suppl 2:41-6, 1994. e-Pub 1994. PMID: 8204519.
260. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF, Jr, Sarris AH, Younes A, Hill D, Cabanillas F. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest New Drugs 12:217-22, 1994. e-Pub 1994. PMID: 7896540.
261. Romaguera JE, Sarris AH, Swan Jr F, Younes A, Hagemeister FB, McLaughlin P, Rodriguez MA, Moore Jr DF, Cabanillas F. Phase I study of protracted 5-fluorouracil infusion in patients with relapsing or refractory lymphoma. J. Infusional Chemotherapy 4:173-176, 1994. e-Pub 1994.
262. Hagemeister FB, Chitin R, Allen P, McLaughlin P, Rodriguez MA. Stage, serum LDH and performance status predict disease progression and survival in HIV-associated lymphomas. Annals of Oncology 5 Suppl 2:41-46, 1994. e-Pub 1994.
263. Preti A, Hagemeister FB, McLaughlin P, Swan F, Rodriguez A, Besa P, Cox JD, Allen PK, Cabanillas F. Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. Ann Oncol 5 Suppl 2:97-100, 1994. e-Pub 1994. PMID: 7515653.
264. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5 Suppl 2:73-7, 1994. e-Pub 1994. PMID: 7515650.
265. McLaughlin P, Cabanillas F, Hagemeister FB, Swan F, Jr, Romaguera JE, Taylor S, Rodriguez MA, Velasquez WS, Redman JR, Gutterman JU. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 4:205-11, 1993. e-Pub 1993. PMID: 7682436.
266. Rodriguez MA, Fuller LM, Zimmerman SO, Allen PK, Brown BW, Munsell MF, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Jr, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 4:125-31, 1993. e-Pub 1993. PMID: 8448080.
267. Seymour JF, Rodriguez MA. Mental neuropathy (numb chin syndrome): a harbinger of tumor progression or relapse. Cancer 71:874-5, 1993. e-Pub 1993. PMID: 8431871.
268. Rodriguez J, Cabanillas F, McLaughlin P, Swan F, Rodriguez M, Hagemeister F, Romaguera J. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 3:711-7, 1992. e-Pub 1992. PMID: 1450060.
269. Hagemeister FB, Fuller L, McLaughlin P, Rodriguez M, Romaguera J, Swan F, Cabanillas F. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann Oncol 3 Suppl 4:87-90, 1992. e-Pub 1992. PMID: 1450086.
270. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Jr, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 10:790-4, 1992. e-Pub 1992. PMID: 1373760.
271. Woo SY, Fuller LM, Cundiff JH, Bondy ML, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Jr, Rodriguez MA, Cabanillas F, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys 23:407-12, 1992. e-Pub 1992. PMID: 1587764.
272. Rodriguez MA, Ford RJ, Goodacre A, Selvanayagam P, Cabanillas F, Deisseroth AB. Chromosome 17- and p53 changes in lymphoma. Br J Haematol 79:575-82, 1991. e-Pub 1991. PMID: 1772779.
273. Litam P, Swan F, Cabanillas F, Tucker SL, McLaughlin P, Hagemeister FB, Rodriguez MA, Velasquez WS. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med 114:855-60, 1991. e-Pub 1991. PMID: 2014946.
274. Velasquez WS, Fuller LM, Jagannath S, Tucker SL, North LB, Hagemeister FB, McLaughlin P, Swan F, Redman JR, Rodriguez MA, et al. Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood 77:942-7, 1991. e-Pub 1991. PMID: 1704805.
275. Robertson LE, Redman JR, Butler JJ, Osborne BM, Velasquez WS, McLaughlin P, Swan F, Rodriguez MA, Hagemeister FB, Fuller LM, et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol 9:236-42, 1991. e-Pub 1991. PMID: 1988571.
276. Hagemeister FB, Fuller LM, Velasquez WS, McLaughlin P, Redman JR, Swan F, Rodriguez MA, North L, Dixon D, Silvermintz K, et al. Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. Ann Oncol 2:25-31, 1991. e-Pub 1991. PMID: 2009233.
277. Hagemeister FB, Cabanillas F, Velasquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodriguez MA, Swan F, Jr, et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol 17:34-8; discussion 38-40, 1990. e-Pub 1990. PMID: 2259922.
278. Cabanillas F, Rodriguez MA, Swan F, Jr. Recent trends in the management of lymphomas at M.D. Anderson Cancer Center. Semin Oncol 17:28-32; discussion 32-3, 1990. e-Pub 1990. PMID: 2259921.
279. Lopez TM, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Redman JR, Rodriguez MA, Tucker SL, Silvermintz K, Johnson J, et al. Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol 8:615-22, 1990. e-Pub 1990. PMID: 2313330.
280. Swan F, Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, Hagemeister FB, Cabanillas F. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518-27, 1989. e-Pub 1989. PMID: 2674337.
281. Cabanillas F, Pathak S, Grant G, Hagemeister FB, McLaughlin P, Swan F, Rodriguez MA, Trujillo J, Cork A, Butler JJ, et al. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med 87:167-72, 1989. e-Pub 1989. PMID: 2757057.
282. Rodriguez MA, Lira P, Foradori A, Grebe G. [Beta 2 microglobulin in some hematologic neoplasms]. Rev Med Chil 116:538-42, 1989. e-Pub 1989. PMID: 2664940.
283. McLaughlin P, Velasquez WS, Redman JR, Yung WK, Hagemeister FB, Rodriguez MA, Cabanillas F. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst 80:1408-12, 1988. e-Pub 1988. PMID: 3172268.
284. Cabanillas F, Velasquez WS, McLaughlin P, Jagannath S, Hagemeister FB, Redman JR, Swan F, Rodriguez MA. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 25:47-50, 1988. e-Pub 1988. PMID: 3041599.

Invited Articles

1. Day S, Bevers TB, Rodriguez MA. Commentary: Are Primary Care Providers Prepared to Care for Survivors of Breast Cancer in the Saftey Net?. Breast Diseases: A Year Book Quarterly 26(4):348-350, 2016. e-Pub 2016.
2. Rodriguez MA Fuller LM. Secondary Malignancies: a risk for survivors of Hodgkin's disease. Diag. Oncol 4:52-57, 1994. e-Pub 1994.
3. Cabanillas F, Rodriguez MA. MINE_ESHAP salvage therapy for recurrent and refractory lymphomas. Sem. Hematol:31-30, 1994. e-Pub 1994.
4. Rodriguez MA, Pentz BD, Stallings CB. Pregnancy and Hodgkin's disease in an 18-year old patient. Cancer Bulletin 46(5):449-451, 1994. e-Pub 1994.
5. Rodriguez A. Un aspecto biológico de los linfomas resistentes a quimiotherapia: La expresión de la ß2-microglobulina. Sangre Trabajos de Hematología y Hemotherapia 35(2):44, 1990. e-Pub 1990.
6. Rodriguez M. Hodgkin's disease. Proceedings of Indo U.S. CME in Medical Oncology:29-41, 1990. e-Pub 1990.
7. Cabanillas F, Rodriguez MA, Swan F. Recent Trends in the Management of Lymphomas at M. D. Anderson Cancer Center. Sem. Oncol 17:28-33, 1990. e-Pub 1990.

Review Articles

1. Skardal A, Sivakumar H, Rodriguez MA, Popova LV, Dedhia PH. Bioengineered in vitro three-dimensional tumor models in endocrine cancers. Endocr Relat Cancer 31(4), 2024. e-Pub 2024. PMID: 38289290.
2. Rodríguez MA, Fernández LA, Daisley BA, Reynaldi FJ, Allen-Vercoe E, Thompson GJ. Probiotics and in-hive fermentation as a source of beneficial microbes to support the gut microbial health of honey bees. J Insect Sci 23(6), 2023. e-Pub 2023. PMID: 38055943.
3. Bravo-Vázquez LA, Mora-Hernández EO, Rodríguez AL, Sahare P, Bandyopadhyay A, Duttaroy AK, Paul S. Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases. Pharmaceutics 15(2), 2023. e-Pub 2023. PMID: 36840033.
4. Bravo-Vázquez LA, Méndez-García A, Rodríguez AL, Sahare P, Pathak S, Banerjee A, Duttaroy AK, Paul S. Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives. Front Bioeng Biotechnol 11:1208547, 2023. e-Pub 2023. PMID: 37576994.
5. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-22, 2003. e-Pub 2003. PMID: 12775737.
6. Rodriguez MA. Factors that influence prognosis of intermediate-grade lymphomas at relapse. Cancer Treat Res 85:79-86, 1996. e-Pub 1996. PMID: 9043776.
7. Rodriguez MA, Pugh WC. Mantle cell lymphomas. Cancer Treat Res 85:41-50, 1996. e-Pub 1996. PMID: 9043774.
8. Sarris AH, Majlis A, Dimopoulos MA, Younes A, Swann F, Rodriguez MA, McLaughlin P, Cabanillas F. Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Leuk Lymphoma 17:473-7, 1995. e-Pub 1995. PMID: 7549840.

Professional Educational Materials

1. Rodriguez MA. Professional Oncology Education Survivorship Lecture Series Webcast, 2010.
2. Rodriguez MA. Professional Oncology Education Survivorship Lecture Series Webcast, 2010.
3. Polansky M, Rodriguez MA. Introduction to Clinical Oncology e-Course, 2009.
4. Sparrow PL, McLaughlin P, Hess M, Temple S, Fayad L, Rodriguez A. Guideline Implementation: Diffuse Large B-Cell Lymphoma, 2007.
5. . Case Study #1: Rituximab Plus GM-CSF for Lymphoma Relapse, 2003.
6. . The ABC’s of Advance Care Planning with Patients: Advantages, Barriers, and Challenges, 2003.
7. . Non-Hodgkin’s Lymphoma: Treatment Guidelines for Patients, 2003.
8. . Clinical Discussion: Diffuse Large B-Cell Lymphoma Guidelines, 2001.
9. . Non-Hodgkin’s Lymphoma: Ifosfamide combinations for salvage chemotherapy. Bristol-Myers Squibb, Princeton, NJ, 1995.

Abstracts

1. Pinnix, Chelsea C, Dabaja, Bouthaina S, Gunther, Jillian R, Fang, Penny, Wu, Susan, Nastoupil, Loretta, Strati, Paolo, Nair, Ranjit, Ahmed, Sairah, Steiner, Raphael E, Malpica-Castillo, Luis, Chihara, Dai, Jain, Preetesh, Fayad, Luis, Westin, Jason R, Neelapu, Sattva S, Rodriguez, Alma M, Hagemeister, Fredrick B, Lee, Ju H, Wang, Michael, Samaniego, Felipe, Fowler, Nathan H, Flowers, Christopher R, Feng, Lei, Chi, Linda, Esmaeli, Bita. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. Blood 138:3526, 2021. e-Pub 2021.
2. Nair, Ranjit, Deen, Nafis, Ahmed, Sairah, Miranda, Roberto N, Fowler, Nathan H, Fayad, Luis, Steiner, Raphael E, Hagemeister, Fredrick B, Rodriguez, Alma M, Lee, Ju H, Strati, Paolo, Malpica-Castillo, Luis, Chihara, Dai, Jain, Preetesh, Gunther, Jillian R, Flowers, Christopher R, Medeiros, Jeffrey L, Nieto, Yago, Ramdial, Jeremy L, Neelapu, Sattva S, Nastoupil, Loretta, Green, Michael R, Wang, Michael, Vega, Francisco, Feng, Lei, Iyer, Padmanabhan S, Westin, Jason R. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood 138:1448, 2021. e-Pub 2021.
3. Cherng, Hua-Jay J, Sun, Ryan, Yang, Haopeng, Deng, Qing, Fayad, Luis, Fowler, Nathan H, Parmar, Simrit, Ahmed, Sairah, Steiner, Raphael E, Hagemeister, Fredrick B, Lee, Ju H, Nair, Ranjit, Rodriguez, Alma M, Samaniego, Felipe, Iyer, Swaminathan P, Nastoupil, Loretta, Neelapu, Sattva S, Strati, Paolo, Westin, Jason R, Green, Michael R. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. Blood 138:38, 2021. e-Pub 2021.
4. Steiner, Raphael E, Strati, Paolo, Flowers, Christopher R, Neelapu, Sattva S, Green, Michael R, Nastoupil, Loretta, Hagemeister, Fredrick B, Feng, Lei, Ahmed, Sairah, Nair, Ranjit, Fayad, Luis, Lee, Ju H, Rodriguez, Alma M, Westin, Jason R. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. Blood 138:1408, 2021. e-Pub 2021.
5. Chihara, Dai, Nastoupil, Loretta, Strati, Paolo, Samaniego, Felipe, Feng, Lei, Rodriguez, Alma M, Fayad, Luis, Westin, Jason R, Hagemeister, Fredrick B, Wang, Michael, Neelapu, Sattva S, Fowler, Nathan H. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma. Blood 138:3532, 2021. e-Pub 2021.
6. Westin, Jason R, Steiner, Raphael, Feng, Lei, Strati, Paolo, Flowers, Christopher R, Neelapu, Sattva S, Nastoupil, Loretta, Chihara, Dai, Hagemeister, Fredrick B, Ahmed, Sairah, Nair, Ranjit, Fayad, Luis, Lee, Ju H, Rodriguez, Alma M, Davis, Eric, Green, Michael R. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. Blood 138:3572, 2021. e-Pub 2021.
7. Gilmore, Ramsey K, Chapman, Hansberry P, Palos, Guadalupe R, Rodriguez, Alma M. Patterns of virtual care among long-term cancer survivors. Journal of Clinical Oncology 39:335-335, 2021. e-Pub 2021.
8. Pundhir P, Ying A, Rodriguez MA, Sturgis E, Andelidakis G, Torres H. Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center. AASLD/EASL HCV Special Conference, 2019. e-Pub 2019.
9. Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad L, Rodriguez MA, Samaniego F, Wang M, Westin J, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic Value of Baseline SUVmax in Patients with Advanced Stage Follicular Lymphoma Receiving Frontline Rituximab-based Therapy. Journal of Clinical Oncology 37(suppl), 2019. e-Pub 2019.
10. Pai A, Ferrajoli A, Cheng L, Huynh T, Rodriguez MA. Comparison of Normal Saline Versus Heparin Flush Solutions for Maintaining Patency of Central Venous Catheter in Cancer Patients. Journal of Clinical Oncology 37(suppl), 2019. e-Pub 2019.
11. Westin J, Nastoupil LJ, Fayad L, Hagemeister FB, Oki Y, Turturro F, Ahmed S, Rodriguez MA, Lee HJ, Steiner R, Nair R, Parmar S, Young KH, McDonnell T, Chuang H, Green MR, Neelapu SS, Davis RE. Smart start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead in Prior to Combination with Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma. Journal of Clinical Oncology 37(suppl), 2019. e-Pub 2019.
12. Rodriguez MA, Palos GR, Gilmore KR, Lewis-Patterson PA, Chapman P, Bi W. Analysis of Financial Sustainability of Survivorship Clinics Led by Advanced Practice Providers. Journal of Clinical Oncology 37(suppl), 2019. e-Pub 2019.
13. Palos GR, Rodriguez MA, Lewis-Patterson P, Harris R, Foxhall L. Factors influencing the use of electronic health record systems to provide follow-up care to cancer survivors. ASCO Quality Care Symposium, 2018. e-Pub 2018.
14. Gilmore KR, Chapman P, Lewis-Patterson P, Rodriguez MA. Understanding the Value of Clinical Survivorship Programs. ASCO Quality Care Symposium, 2018. e-Pub 2018.
15. Rodriguez MA, Palos GR, Gilmore KR, Lewis-Patterson P, Foxhall L, Shay L. Family medicine providers' perceptions of their ability to provide evidence-based survivorship care. ASCO Annual Meeting, 2018. e-Pub 2018.
16. Palos GR, Hutcheson KA, Pytynia KB, Schreiner C, Gilmore KR, Chapman P, Bi W, Lewis-Patterson P, Goepfert R, Rodriguez MA. Symptoms burden reported by head and neck cancer patients at their first survivorship clinic visit. ASCO Annual Meeting, 2018. e-Pub 2018.
17. Rodriguez MA. A Statewide Tele-Mentoring Medical Education Program to Improve Survivorship Care. Sixth State of the Science Cancer Survivorship Research Symposium: Translating Cancer Survivorship and Energy Balance Research into Public Health Initiatives, 2018. e-Pub 2018.
18. Rodriguez MA, Palos GR, Gilmore KR, Chapman P, Lewis-Patterson P, Bi W. Patterns of concordance with clinical algorithms for survivors of head and neck cancers. ASCO Cancer Survivorship Symposium: Advancing Care and Research, 2018. e-Pub 2018.
19. Rodriguez MA, Palos GR, Foxhall L, Gilmore KR, Harris R, Lewis-Patterson P, Shay L. A Statewide Tele-Mentoring Medical Education Program to Improve Survivorship Care. 2nd Victorian Cancer Survivorship Conference: The Survivorship Equation, 2018. e-Pub 2018.
20. Rodriguez MA, Palos GR, Gilmore KR, Chapman P, Lewis-Patterson P, Bi W. Family medicine providers' perceptions of their ability to provide evidence-based survivorship care. ASCO Cancer Survivorship Symposium: Advancing Care and Research, 2018. e-Pub 2018.
21. Rodriguez MA, Foxhall L, Shay A, Gilmore K, Harris R, Lewis-Patterson P, Palos GR. A Statewide Tele-Mentoring Medical Education Program to Improve Survivorship Care. CPRIT Innovations In Cancer Prevention and Research Conference, 2017. e-Pub 2017.
22. Rodriguez MA, Palos GR, Gilmore KR, Chapman P, Lewis-Patterson P. Measuring Concordance with Head and Neck Cancer Survivorship Algorithms. 2017 ASCO Annual Meeting, 2017. e-Pub 2017.
23. Gilmore KR, Choi DK, Chapman P, Lewis-Patterson P, Palos GR, Rodriguez MA. The Use of Electronic Health Record Systems to Create Treatment Summaries and Survivorship Care Plans. GAP 2017 Conference, 2017. e-Pub 2017.
24. Rodriguez MA, Suarez-Almazor ME, Lewis-Patterson P, Palos GR. A novel strategy to build research capacity in survivorship science. GAP 2017 Conference, 2017. e-Pub 2017.
25. Palos GR, Chapman P, Gilmore KR, Lewis-Patterson P, Rodriguez MA. An educational program to improve cancer survivorship research. 2017 ASCO Quality Care Symposium, 2017. e-Pub 2017.
26. Palos GR, Gilmore KR, Chapman P, Lewis-Patterson P, Rodriguez MA. Improving Survivors' Outcomes in Cancer Survivorship Clinics. 2017 ASCO Quality Care Symposium, 2017. e-Pub 2017.
27. Rodriguez MA, Suarez-Almazor ME, Lewis-Patterson P, Palos GR. A novel strategy to build research capacity in survivorship science. 2017 ASCO Cancer Survivorship Meeting, 2017. e-Pub 2017.
28. Gilmore KR, Choi DK, Chapman P, Lewis-Patterson P, Palos GR, Rodriguez MA. The Use of Electronic Health Record Systems to Create Treatment Summaries and Survivorship Care Plans. 2017 ASCO Cancer Survivorship Meeting, 2017. e-Pub 2017.
29. Palos GR, Lewis-Patterson P, Gilmore K, Chapman P, Bi W, Rodriguez MA. Providers' Adherence to Surveillance Recommendations for Colorectal Cancer Survivors. ASCO Annual Meeting, 2016. e-Pub 2016.
30. Palos GR, Lewis-Patterson P, Gilmore K, Chapman P, Bi W, Rodriguez MA. Do Survivors Follow Recommendations for Colorectal Cancer Surveillance Reviewed during Survivorship Clinic Visits?. 8th Biennial Cancer Survivorship Research Conference: Innovation in a Rapidly Changing Landscape, 2016. e-Pub 2016.
31. Gilmore KR, Palos GR, Lewis-Patterson P, Chapman P, Jones D, Bi W, Rodriguez MA. Development and Use of Survivorship Care Plans to Enhance Care After Cancer Treatment. Annual Global Academic Program (GAP) 2016, 2016. e-Pub 2016.
32. Gilmore KR, Palos GR, Lewis-Patterson P, Chapman P, Jones D, Bi W, Rodriguez, MA. Development and Use of Survivorship Care Plans to Enhance Care After Cancer Treatment. Fourth State of the Science Cancer Survivorship Research Symposium, 2016. e-Pub 2016.
33. Lewis-Patterson PA, Palos GR, Gilmore KR, Chapman, Jones D, Bi W, Rodriguez MA. Using Clinical Algorithms to Identify Psychosocial Distress and Other Risk Factors in Cancer Survivors. Fourth State of the Science Cancer Survivorship Research Symposium, 2016. e-Pub 2016.
34. Palos G, Zandstra FA, Simar KA, Russell L, Ozeri D, Bi W, Rodriguez MA. Tobacco Use among Lymphoma Survivors. Fourth State of the Science Cancer Survivorship Research Symposium, 2016. e-Pub 2016.
35. Palos G, Gilmore KR, Chapman P, Lewis-Patterson P, Bi W, MARodriguez. Low concordance with CEA tumor marker monitoring in colorectal cancer survivors. AACR Annual Meeting, 2016. e-Pub 2016.
36. Bell, M, Stepan, K, Meyer, M, Anderson, J, Calhoun, J, Guzman, A, Thomas, J, Rodriguez, MA, Valentine A, A. Defining the Value of Psychosocial Services for Cancer Care Patients. International Psycho-Oncology Congress Conference, 2016. e-Pub 2016.
37. Bell, M, Stepan, K, Meyer, M, Anderson, J, Calhoun, J, Guzman, A, Thomas, J, Rodriguez, MA, Valentine A, A. Building the Case for a Value-Based Integrated Mental Health Services Access and Financial Model for a Comprehensive Cancer Center. International Psycho-Oncology Congress Conference, 2016. e-Pub 2016.
38. Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil L, Fowler N, Turturro F, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience. Blood 128(22):4208, 2016. e-Pub 2016.
39. Palos GR, Hebdon M, McComb S, Wagner RW, Gilmore KR, Rodriguez MA. Perceptions of Providers and Survivors' towards Dedicated Survivorship Care Clinics. ASCO Quality Care Symposium, 2015. e-Pub 2015.
40. Gilmore K, Chapman P, Cleveland D, Lewis-Patterson P, Palos GR, Rodriguez MA. Leveraging Web-Based Interface Systems with Institutional Databases to Improve Compliance with Survivorship Care Plans. ASCO Quality Care Symposium, 2015. e-Pub 2015.
41. Palos GR, Gilmore KR, Chapman P, Lewis-Patterson P, Rodriguez MA. Application of a Standard Practice-Based System to Measure and Compare Quality of Cancer Survivorship Car. ASCO Quality Care Symposium, 2015. e-Pub 2015.
42. Palos GR, Gilmore K, Chapman P, Bi W, Jones D, Rodriguez MA. Adherence with distress screening in post-treatment survivors diagnosed with colorectal cancer. The Advances In Cancer Survivorship Practice: A Conference For Health Care Professionals, 2015. e-Pub 2015.
43. Palos GR, Gilmore KR, Lewis-Patterson P, Rodriguez MA. Cancer Survivorship Algorithms as Clinical Tools for Primary Care Providers. ASCO 2016 Cancer Survivorship Symposium: Advancing Care and Research, 2015. e-Pub 2015.
44. Palos GR, Hebdon M, McComb S, Wagner RW, Rodriguez MA. Survivors' Narratives of the Values of Cancer Survivorship Care Plan and Clinical Services. ASCO 2016 Cancer Survivorship Symposium: Advancing Care and Research, 2015. e-Pub 2015.
45. Palos GR, Zandstra F, Russell L, Gilmore K, Flores J, Rodriguez M. Planning cancer wellness survivorship programs for community-based adult survivors. The Advances In Cancer Survivorship Practice: A Conference For Health Care Professionals, 2015. e-Pub 2015.
46. Palos GR, Lewis-Patterson P, Chapman P, Gilmore KR, Rodriguez MA. Enhancing the cancer survivors' with tailored supportive services. ASCO Palliative Care in Oncology Symposium, 2015. e-Pub 2015.
47. Gilmore KR, Palos GR, Lewis-Patterson P, Chapman P, Jones D, Bi W, Rodriguez MA. Development and Use of Survivorship Care Plans to Enhance Care After Cancer Treatment. ASCO Palliative Care in Oncology Symposium, 2015. e-Pub 2015.
48. Lewis-Patterson P, Palos GR, Gilmore KR, Chapman P, Bi W, Jones D, Rodriguez MA. Using clinical algorithms to identify psychosocial distress and other risk factors in cancer survivors. ASCO Palliative Care in Oncology Symposium, 2015. e-Pub 2015.
49. Palos GR, Simar K, Russell L, Jones D, Weiqi B, Rodriguez MA. Tobacco use among lymphoma survivors. 3rd Conference on Medical Issues in Cancer Patients and Survivors, 2015. e-Pub 2015.
50. Palos GR, Gilmore K, Chapman P, Wirqi B, Jones D, Rodriguez MA. Adherence with distress screening in post-treatment survivors diagnosed with colorectal cancer. American Psychosocial Oncology Society, 2015. e-Pub 2015.
51. Palos GR, Gilmore K, Chapman P, Weiqi B, Jones D, Rodriguez MA. Surveillance of Long-Term Colorectal Cancer Survivors. American Society of Clinical Oncology (ASCO) Annual Meeting, 2015. e-Pub 2015.
52. Palos GR, Zandstra F, Russell L, Gilmore K, Flores J, Jones D, Leong C, Nguyen J, Patel M, Rodriguez MA. Planning cancer wellness survivorship programs for community-based adult survivors. Annual GAP Conference 2015, 2015. e-Pub 2015.
53. Palos GR, Zandstra F, Bevers T, Gilmore K, Greer M, Rodriguez MA. Improving Survivors' Quality of Care Through Use of Self-Reported Satisfaction Data. AACR Journal Cancer Research, 2015. e-Pub 2015.
54. Stepan, KA, Tortorella, F, Rodriguez A, MA. Building an Infrastructure and Measuring the Implementation of Advance Care Planning in the Oncology Practice Setting. World Congress of Psycho-Oncology (IPOS/APOS) and International Cancer Conference, 2015. e-Pub 2015.
55. Stepan, KA, Tortorella, F, Rodriguez, MMA. A Psychosocial Council: Meeting the Challenges of Providing Psychosocial Care. International Cancer Education Conference, 2014. e-Pub 2014.
56. Rodriguez MA, Sanchez-Espiridion B, Gu J, Wu X, Zandstra F, Palos G. Leukocyte telomere length and risk of secondary primary tumors in long-term breast cancer suvivors. J Clin Oncol 32(5s):626s, 2014. e-Pub 2014.
57. Rodriguez MA, DeJesus AY, Cheng L, Kroll M. Practice of venous thromboembolism (VTE) prophylaxis in hospitalized cancer patients at a comprehensive cancer center. J Clin Oncol 32(5s):440s, 2014. e-Pub 2014.
58. Nastoupil L, Neelapu S, Samaniego F, Hagemeister F, Romaguera J, Kwak L, Wang M, Fayad L, Fanale M, Oki Y, Westin J, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler N. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabne, mitozantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32(5s):545s, 2014. e-Pub 2014.
59. Palos G, Zandstra F, Simar K, Russell L, Ozeri D, Bi W, Rodriguez MA. Tobacco use among lymphoma survivors. J Clin Oncol 32(suppl), 2014. e-Pub 2014.
60. Fingeret M, Palos GR, Stepan K, Tortorella F, Rodriguez MA. Establishment and Growth of a Psychosocial Council to Address Institutional Needs Within a Comprehensive Cancer Center. Psycho-Oncology 23(Supp S1):22-23, 2014. e-Pub 2014.
61. Zhou Z, Sehn LH, Radmaker A, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Rodriguez MA, Zelenetz AD, Abel GA, Nademanee A, Kaminski MS, Czuczman M, Millenson MM, Niland JC, Gascoyne RD, Connors JM, Friedberg J, Winter JN. An Enhanced International Prognostic Index (NCCN-IPI) for Risk Stratification of Diffuse Large B-cell Lymphoma Patients in the Rituximab Era: Validation Using the British Columbia Cancer Agency Database. Hematol Oncol 31(S1):166, 2013. e-Pub 2013.
62. Zandstra F, Palos G, Russell L, Gilmore K, Flores J, Ozeri D, Rodriguez MA. Providers' Concordance with Survivorship Clinical Algorithms. 2013 ASCO Annual Meeting Proceedings 31(15 (Suppl)), 2013. e-Pub 2013.
63. Dabaja B, Vanderplas A, Abel G, Czuczman MS, Friedberg J, Gordon LI, Kaminski M, LaCasce AS, Millenson M, Niland J, Nademanee AP, Zelenetz A, Crosby-Thompson AL, Rodriguez MA. Role of Radiation in Patients with Diffuse Large B-cell Lymphoma (DLBCL) in the Rituximab Era: A Comprehensive Analysis from the National Comprehensive Cancer Network (NCCN) Lymphoma Outcomes Project. Hematolo Oncol 31(S1):136, 2013. e-Pub 2013.
64. Zhou Z, Rademaker A, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Rodriguez MA, Zelenetz AD, Abel A, Nademanee A, Kaminski MS, Cuzczman M, Milleson MM, Niland JC, Friedberg JW, Winter JN. Impact of Gender, Body Mass Index and Body Surface Area on Outcomes of Diffuse Large B-cell Lymphoma Patients Treated with Rituximab: Analysis of the U.S. National Comprehensive Cancer Network Database. Hematol Oncol 31(S1):166, 2013. e-Pub 2013.
65. Burke T, DeJesus Y, Cheng L, Buzdar A, Rodriguez MA. Pattern of Chemotherapyuse at the End-of-life in Patients with Solid Tumors (ST). 2013 ASCO Annual Meeting Proceedings 31(15 (Suppl)), 2013. e-Pub 2013.
66. Rodriguez MA, DeJesus YA, Cheng L, Buzdar A, Burke T. Factors Related to End-of-life Chemotherapy in Solid Tumor (ST) Patients. 2013 ASCO Annual Meeting Proceedings 31(15(Suppl)), 2013. e-Pub 2013.
67. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera J, McLaughlin P, Samaniego F, Kwak L, Hagemeister F. Comparison of the International Prognostic Factors Index (IPI) with the Absolute Monocyte and Lymphocyte Prognostic Index (AMLPI) for Patients (Pts) with Diffuse Large B-cell (DLBCL) Receiving R-CHOP. 2012 ASCO Annual Meeting Proceedings 30(15 (Suppl)), 2013. e-Pub 2013.
68. Palos GR, Zandstra F, Russell L, Flores J, Gilmore K, Rodriguez MA. Evaluating Survivorship Cancer Care Through Quality Improvement Programs. J Clin Oncol, 2012 ASCO Quality Care Symposium Abstracts 30(34 (December 1 Suppl)), 2012. e-Pub 2012.
69. Rodriguez MA, DeJesus Y, Cheng L. Chemotherapy Use During the Last 30 Days of Life in Patients with Cancer. J Clin Oncol, 2012 ASCO Quality Care Symposium Abstracts 30(34 (December 1 Suppl)), 2012. e-Pub 2012.
70. Fanale M, Chao-Ming L, Rimes S, Ramirez M, Hagemeister FB, Fowler N, Younes A, Fayad L, Rodriguez MA, Turturro F, Samaniego F, Romaguera J, Levin V, Horowitz S, Woolery J, Milbourne A. Positive Maternal-Fetal Outcomes with Treatment ofLymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
71. Oki Y, Westin J, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera J, Fanale M, Younes A, Rodriguez MA, Orlowski R, Wang M, Ouzounian S, Samaniego F, Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (Pts) with IH and High-Risk Age Adjeusted-IPI in Younger DLBCL. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
72. Zhou Z, Rademaker A, Gordon L, LaCasce A, Vanderplas A, Crosby-Thompson A, Zelentz A, Abel G, Rodriguez MA, Nademanee A, Kaminski M, Czuczman M, Millenson M, Niland J, Friedberg J, Winter J. An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
73. Ban-Hoefen M, Vanderplas A, Kelly J, Crosby-Thompson A, Abel G, Czuczman M, Gordon L, Kaminski M, Millenson M, Nademanee A, Rodriguez MA, Zelenetz A, Niland J, LCasce A, Friedberg J. Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
74. Palos G, Zandstra F, Russell L, Flroes J, DeJesus Y, Foxhall L, Rodriguez MA. Using Practice Algorithms to Deliver Cancer Survivorship. 2012 ASCO Annual Meeting Proceedings 30(Suppl), 2012. e-Pub 2012.
75. Rodriguez MA, DeJesus Y, Cheng L, Burke T. Chemotherapy Within the Last 30 Days of Life Among patients with Metastatic Solid Tumors. 2012 ASCO Annual Meeting Proceedings 30(Suppl), 2012. e-Pub 2012.
76. Zandstra F, Palos G, Russell L, Flores J, DeJesus Y, Foxhall L, Rodriguez MA. Multidisciplinary Care Clinics: A Model to Deliver Personalized Survivorship Care. 2012 ASCO Annual Meeting Proceedings 30(Suppl), 2012. e-Pub 2012.
77. LaCasce A, Vandergrift JL, Rodriguez MA, Crosby AL, Lepisto EM, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Abel GA, Zelenetz AD, Friedberg JW. R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: A Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin’s Lymphoma Outcomes Database Project. Blood 114(22), 2009. e-Pub 2009.
78. Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister F. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood 114(22), 2009. e-Pub 2009.
79. Copeland AR, Cao Y, Fanale M, Fayad L, McLaughlin P, Pro B, Hagemeister F, Romaguera J, Samaniego F, Rodriguez A, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Results of Long Follow Up and Comparison to Institutional Historical Data. Blood 114(22), 2009. e-Pub 2009.
80. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister FB. Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors. Blood 114(22), 2009. e-Pub 2009.
81. Abel GA, Vanderplas A, Friedberg JW, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby AL, Gordon LI, BlayneyDW, Zelenetz AD, LaCasce AS. Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. Blood 114(22), 2009. e-Pub 2009.
82. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Bueso-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera J. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing vs. a Single Dose Followed By As Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Blood 114(22), 2009. e-Pub 2009.
83. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin PW, Pro B, Wang M, Rodriguez A, Hagemiester FB, Macapinlac HA, Podoloff DA, Champlin RE, Khouri IF. Zevalin/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT): Impact of the IPI and PET Status. Blood 110(11), 2007. e-Pub 2007.
84. Rodriguez MA, Fanale M, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Kwak L, Fayad L, Huang X, Durand JB. Phase II Study of RCHOP with Pegylated Liposomal Doxuribicin (DRCOP) for Patients >60 Years Old with Untreaed Diffuse Large B Cell Lymphoma (DLBCL). Blood 110(11), 2007. e-Pub 2007.
85. Fayad L, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak L, Romaguera J, Rodriguez MA. R-HCVAD/R-MTX-ARAC is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger than 60 Years. Blood 110(11), 2007. e-Pub 2007.
86. Thomas DA, Kantarjian H, Cortes J, Faderl S, Ravandi-Kashani F, Wierda W, Rodriguez A, Fayad L, O'Brien S. Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (B-ALL). Blood 110(11), 2007. e-Pub 2007.
87. Rodriguez MA, Winter JN, Biah L, Huang G, Choy GS, Deitcher SR. Marqibo (Vincristine Sulfate Liposomes Injection (OPTISOME) Demonstrates Activity in Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma. Blood 110(11), 2007. e-Pub 2007.
88. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood 110(11), 2007. e-Pub 2007.
89. Pro B, Fayad L, Romaguera J, Fanale M, Younes A, Hagemeister FB, Samaniego F, McLaughlin P, Rodriguez MA, Kwak L, Dang NH. Preliminary Results of a Phase II Study of HCVID Doxil Alternated with Methtrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. Blood 110(11), 2007. e-Pub 2007.
90. Wedgwood AR, Fanale MA, Fayad LE, McLaughlin P, Hagemeister FB, Pro B, Romaguera J, Rodriguez MA, Samaniego F, Younes A. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2-3 Cycles of Therapy. Blood 110(11), 2007. e-Pub 2007.
91. Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaguhlin P, Wang M, Kwak L, Romaguera J, Rodriguez MA. R-YCVAD/R-MTX-ARAC is An Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features: M.D. Anderson Experience in 40 Patients. Journal of Clinical Oncology 25(18S), 2007. e-Pub 2007.
92. Rodriguez MA, Temple S, Fayad L, Hagemeister F, McLaughlin P, Romaguera J, Cabanillas F. Predictive Value for Survival of a Risk Model of Two Serological Markers, Beta-2-Microglobulin (B2M) and Lactic Dehydrogenase (LDH), in Diffuse Large Cell Lymphoma (DLCL). Journal of Clinical Oncology(25):18S, 2007. e-Pub 2007.
93. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Podoloff D, Samuels B, Loyer E, Zhou Y, Younes A. Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (ZevalinR) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). Blood 108(11):Abstract 2714, 2006. e-Pub 2006.
94. Samaniego F, Fayad L, Barbara P, McLaughlin P, Rodriguez MA, Hagemeister FB, Fanale M, Neelapu, Younes A, Kwak LW. Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma. Blood 108(11):Abstract 4722, 2006. e-Pub 2006.
95. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris SH, Dang NH, Wang L, Kantarjian H, Beasley V, Medeiros LJ, Katz R, Cabanillas F. Blastoid Mantle Cell Lymphoma (MDL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab R-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood 108(11):Abstract 2749, 2006. e-Pub 2006.
96. Falchook G, Champlin R, Hagemeister FB, Hosing C, Kwak L, O'Brien S, Rodriguez MA, Verstovsek S, Barbara P. Hepatosplenic T-Cell Lymphoma. Blood 108(11):Abstract 2460, 2006. e-Pub 2006.
97. Kadia T, Fayad L, Rodriguez MA, McLaughlin P, Pro B. Retrospective Review of Angiommunoblastic T-Cell Lymphoma: The MD Anderson Cancer Center Experience. Blood 108(11):Abstract 4690, 2006. e-Pub 2006.
98. Fayad L, Overman M, Pro B, McLaughlin P, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Rodriguez MA. Favorable Results of Rituximab in Combination with CHOP in the Front Line Treatment of Follicular Lymphoma Grade 3. Blood 108(11):Abstract 2770, 2006. e-Pub 2006.
99. Fayad L, Pro B, Liu Q, Hess M, Hagemeister F, Romaguera J, Samaniego F, Cabanillas F, Rodriguez M, Younes A, Wang M, McLaughlin P. Time to Treatment Failure (TTF) and FLIP1 Correlate Well with Survival and Are independent Variables in Stage IV Indolent Follicular Lymphomas (IFL). Blood 106(11):Abstract 933, 2005. e-Pub 2005.
100. Rodriguez MA, Czuczman M, Friedberg J, Kho M, LaCasce A, Millenson M, Auayporn N, Niland J, Ter Veer A, Zelenetz A, Weeks J. Age Significantly Influences Presentation and Patterns of Care in Patients with Newly Diagnosed Diffuse Large Cell Lymphoma (DLCL): Collective Data from5 Centers Participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project. Blood 106(110:Abstract 1335, 2005. e-Pub 2005.
101. Younes A, McLaughlin P, l F, Goy A, Romaguera J, Pro B, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros J. Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab. Blood 106(11):Abstract 1499, 2005. e-Pub 2005.
102. Rodriguez A. Phase II Study of Sphingosomal Vincristine in CHOP+/-Rituximab for Patients with Aggressive Hon-Hodgkin's Lymphoma (NHL): Promising 3 year Follow-Up results in Elderly Patients. Blood 106(11):Abstract 943, 2005. e-Pub 2005.
103. Hagemeister F, McLaughlin P, Fayad L, Samaniego F, Dang N, Goy A, Romaguera J, Pro B, Beasley V, Cabanillas F, Rodriguez M. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL). Blood 106(11):Abstract 941, 2005. e-Pub 2005.
104. Habra MA, Thompson MA, Rodriguez MA, Routbort MJ, Holsinger FC, Perrier ND, Rare Disorder WSPNKCLOTAGAUPOA. Primary Natural Killer/T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of a Rare Disorder. The Endocrine Society's 87th Annual Meeting 87th Annual Meeting, 2005. e-Pub 2005.
105. Pro B, Smith MR, Leber B, Younes A, Fayad L, Hagemeister FB, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. Phase II Study of Oblimersen Sodium and Rituximab in Patients with Recurrent B-cell Non-Hodgkin’s Lymphoma. 2005 ASCO Annual Meeting Proceedings, JCO 23(16S), 2005. e-Pub 2005.
106. Rodriguez MA Sarris A. Integrated Efficacy Results from Two Phase II Studies Utilizing Sphingosomal Vincristine for the Treatment of Multiply Relapsed or Refractory Non-Hodgkin’s Lymphoma. 2005 ASCO Annual Meeting Proceedings, JCO 23(16S), 2005. e-Pub 2005.
107. Rodriguez MA, Sarris A, Dang NH, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Samaniego F, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP +/- Rituximab Is a Promising New Treatment for Patients with High Risk Untreated Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results of a Phase II Study. Blood 104(11), 2004. e-Pub 2004.
108. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Medeiros LJ, Katz R, Gagneja H, Samuels BI, Cabanillas F. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS). Blood 104(11), 2004. e-Pub 2004.
109. Dang NH, Pro B, Hagemeister FB, Jones D, Samuels B, Rodriguez MA, Goy A, Romaguera JE, Walker PL, Kwak L, Fayad L. Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma. Blood 104(11), 2004. e-Pub 2004.
110. Rodriguez MA Winter JN. Treatment Response to Single Agent Sphingosomal Vincristine in Patients with Relapsed and/or Refractory Diffuse Aggressive Non-Hodgkin’s Lymphoma (NHL): Subgroup Analysis. Blood 104(11), 2004. e-Pub 2004.
111. Pro B, Smith MR, Younes A, Fayad LE, Goy AH, Hagemeister FB, McLaughlin P, Rodriguez MA, Frankel SR, Zwiebel JA. Oblimersen Sodium (Bcl-2 antisense) Plus Rituximab in Patients With Recurrent B-Cell Non-Hodgkin’s Lymphoma: Preliminary Phase II Results. 2004 Annual Meeting of the American Society of Clinical Oncology, Journal of Clinical Oncology 22(14S), 2004. e-Pub 2004.
112. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a Phase (ph) 2 Study of Bortezomib in Patients (pts) With Relapsed or Refractory Indolent or Aggressive Non-Hodgkin’s Lymphoma (NHL). 2004 Annual Meeting of the American Society of Clinical Oncology, Journal of Clinical Oncology 22(14S), 2004. e-Pub 2004.
113. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP Is A Promising New Treatment For Elderly, As Well As Poor Prognosis Patients With Aggressive Non-Hodgkin’s Lymphoma (NHL): Follow-Up Results Of A Phase II Study. 2004 Annual Meeting of the American Society of Clinical Oncology, Journal of Clinical Oncology 22(14S), 2004. e-Pub 2004.
114. Sarma A, Rodriguez MA, Cabanillas F, Dang NH, McLaughlin P, Hagemeister FB, Pro B, Romaguera J, Younes A, Grimm EA. A Randomized Trial of CHOP Chemotherapy With or Without Melatonin in Patients With Favorable Prognosis Large B-Cell Lymphoma. 2004 Annual Meeting of the American Society of Clinical Oncology, Journal of Clinical Oncology 22(14S), 2004. e-Pub 2004.
115. Friedberg JW, Kho ME, Lepisto E, Rodriguez MA, TerVeer A, LaCasce AS, Nademanee AP, Millenson M, Czuczman M, Niland J, Zelenetz AD, Weeks JC. Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Follicular (FL), Mantle Cell (MCL), and Diffuse Large B Cell (DLCL) Non-Hodgkin’s Lymphoma (NHL) in 5 United States Comprehensive Cancer Centers: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. Blood104 11:November 16, 2004. e-Pub 2004.
116. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L. Taxol Plus Topotecan Plus Rituximab (TTR) with G-CSF Support An Effective Salvage Program for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL) Who Failed CHOP-Like and Platinum-Based Therapy. Blood 102(11), 2003. e-Pub 2003.
117. Goy A, Hart S, Tiongson LP, Fayad L, Romaguera J, Younes A, Dang N, Preti A, Samuels B, Sarris A, Gilles F, Rodriguez MA. Preliminary Report of a Phase II Study of Vincristine Sulfate Liposomes Injection (VSLI) in Patients with Relapsed or Refractory Hodgkin’s Disease. Blood 102(11), 2003. e-Pub 2003.
118. Pro B, Smith MR, Younes A, Dang NH, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Rodriguez MA, Samuels B, Arredondo Y, Frankel SR, Zwiebel JA. Genasense (Bcl-2 Antisense) Plus Rituximab Is Active in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma. Blood 102(11), 2003. e-Pub 2003.
119. Dang NH, Hagemeister FB, Fayad L, Pro B, McLaughlin P, Romaguera JE, Samaniego F, Goy A, Wang M, Walker PL, Samuels B, Jones D, Rodriguez MA. Analysis of a Phase II Study of Denileukin Diftitox (ONTAK) for B and T-Cell Non-Hodgkin’s Lymphoma. Blood 102(11), 2003. e-Pub 2003.
120. Friedberg JW, Lepisto E, Rodriguez MA, Ottensen R, Czuczman M, Niland J, Zelenetz AD, Weeks J. Utilization of Rituximab Therapy in Patients (pts) with Newly Diagnosed Follicular (FL) and Diffuse Large B Cell (DLCL) Non-Hodgkin’s Lymphoma (NHL) in the United States: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. Blood 102(11), 2003. e-Pub 2003.
121. Goy A, Bleyer A, Hagemeister F, Fayad L, Pro B, Romaguera J, Samaniego F, Sarris AH, Hart S, Cabanillas F, Murgo A, Duvic M, Rodriguez MA. Phase II Study of Compound GW506U78 (AraG) for Patients with Indolent B-Cell or Peripheral T-Cell Lymphoma Previously Treated with Chemotherapy. Blood 102(11), 2003. e-Pub 2003.
122. Rodriguez MA, Van Besien K, Hagemeister FB, Giralt S, McLaughlin P, Gajewski JL, Romaguera J, Khouri IF, Younes A, Cabanillas FC, Champlin R. Randomized Comparison of Frontline Alternating Chemotherapy (ATT) Versus Brief Induction Followed by Autologous Stem Cell Transplant (ASCT) for Aggressive Lymphomas. Blood 102(11), 2003. e-Pub 2003.
123. Liu NS, Grimm E, Poindexter N, Rodriguez MA, Hagemeister FB, Pro B, Fayad L, Lee BN, Reuben JM, McLaughlin P. Antibody Dependent Cellular Cytotoxicity and Natural Killer Cell Activity in Patients with Recurrent Indolent Lymphoma Receiving Rituximab in Combination with GM-CSF. Blood 102(11), 2003. e-Pub 2003.
124. Qi L, Fayad L, Hagemeister FB, Rodriguez MA, Younes A, Pro B, Verstovsek S, Cabanillas F, Tsimberidou A, Hess M, Ayala A, Clemons A. Stage IV Indolent Lymphoma: 25 Years of Treatment Progress. Blood 102(11), 2003. e-Pub 2003.
125. Kurbegov D, Cabanillas, Dang NH, a G, McIntyreB, McLaughlin P, Pro B, Rodriguez MA, Romaguera JE, Fayad L. Elevated Serum soluble CD44 (sCD44) Level Is Associated with Unfavorable Features, Shorter Relapse-Free Survival, and Worse Overall Survival in Patients with Indolent Non-Hodgkin’s Lymphomas (NHL). Blood 102(11), 2003. e-Pub 2003.
126. Pro B, Cabanillas F, Dang NH, Fayad LE, Goy A, McLaughlin P, Rodriguez MA, Romaguera J, Samaniego F, Wu HH, Hess M, Gold DL, Hagemeister FB. Prognostic Factors in Follicular Lymphoma: The Importance of Beta-2 Microglobulin. Blood 102(11), 2003. e-Pub 2003.
127. Cohen L, Warneke C, Fouladi R, Rodriguez MA, Chaoul-Reich A. A Tibetan yoga program for cancer patients. Psychosomatic Medicine 65(1):A22, 2003. e-Pub 2003.
128. Cohen L, Warneke C, Fouladi R, Rodriguez, MA, Chaoul-Reich A. A Tibetan yoga intervention for cancer patients. Pyscho-oncology 12(4):S132, 2003. e-Pub 2003.
129. Wang ML, Roifman C, Harris DM, Grunberger T, Demin P, Van Q, Rodriguez MA, Talpaz M, Estrov Z. CR4, a novel protein kinase inhibitor inhibits STAT3 phosphorylation, suppresses proliferation and induces apoptosis in diffuse large B cell lymphoma cells. Proceedings of ASCO 22, 2003. e-Pub 2003.
130. Medeiros LJ, Cabanillas F, M-S L, Rodriguez MA, Hagemeister FB, Romaguera J, Hess M, Ayala A, McLaughlin P. Prognostic relevance of t914;18) status in follicular lymphoma (FL). Proceedings of ASCO 22, 2003. e-Pub 2003.
131. Dang NH, Hagemeister F, Fayad L, Pro B, McLaughlin P, Romaguera J, Samaniego F, Younes A, Goy A, Rodriguez MA. Interim analysis of a phase II study of denileukin diftitox (ONTAK) for B and T-cell non-Hodgkin’s lymphoma. Proceedings of ASCO 22, 2003. e-Pub 2003.
132. McLaughlin, P, Rodriguez MA, Hagemeister FB, Romaguera J, Sarris AH, Younes A, Dang NH, Goy A, Samaniego F, Hess M, others. Stage IV indolent lymphoma: A randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. Proceedings of ASCO 22, 2003. e-Pub 2003.
133. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Hosing C, Donato ML, Pro B, Couriel D, Rodriguez M, Korbling M, Cabanillas F, Ruth K, Champlin R. Nonablative Allogeneic Stem Cell Transplantation for Relapsed Mantle Cell Lymphoma (MCL): A Promising Strategy for an Aggressive Disease. Blood 100(11), 2002. e-Pub 2002.
134. Younes A, Fayad L, McLaughlin P, Goy AH, Romaguera J, Rodriguez MA, Hagemeister FB, Samaniego F, Pro B, Medeiros LJ, Ha C, Wilder R, Seifert A. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease. Blood 100(11), 2002. e-Pub 2002.
135. Pro B, Romaguera J, Macapinlac H, Fayad L, Dang N, Samaniego F, Goy A, Rodriguez MA, McLaughlin P, Podoloff D, Cabanillas F. Positron Emission Tomography (PET) Using Fluorodeoxyglucose but not Gallium-67 Scintigraphy is a Sensitive Imaging Modality in the Staging of Mantle Cell Lymphoma (MCL). Blood 100(11), 2002. e-Pub 2002.
136. Younes A, Robertson MJ, Flinn IA, Romaguera J, Hagemeister FB, Cabanillas F, Rodriguez MA, Dang N, Samaniego F. A Phase II Study of Interleukin-12 (IL-12) in Patients with Relapsed Non-Hodgkin Lymphoma and Hodgkin Disease. Blood 100(11), 2002. e-Pub 2002.
137. Rodriguez MA, Sarris A, East K, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera J, Samaniego F, Younes A, Cabanillas F. A Phase II Study of Liposomal Vincristine in CHOP with Rituximab for Patients with Untreated Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL): A Safe and Effective Combination. Blood 100(11), 2002. e-Pub 2002.
138. Khouri IF, Saliba RM, Hosing C, G-J O, Donato ML, Younes A, Acholonu S, McLaughlin P, Andersson B, Rodriguez MA, Korbling M, Cabanillas F, Champlin R. Concurrent Administration of High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stem Cell Transplantation (ASCT) for Relapsed B-Cell Lymphomas: Increased Efficacy without Added Toxicity. Blood 100(11), 2002. e-Pub 2002.
139. Younes A, Hagemeister F, Romaguera J, Samaniego F, McLaughlin P, Rodriguez MA, Medeiros LJ, LaMotte C, Ha C, Wilder R, Cabanillas F. Interferon Alpha Plus ABVD for the Treatment of Patients with Classical Hodgkin Disease. Blood 100(11), 2002. e-Pub 2002.
140. Hagemeister FB, McLaughlin P, Clemons M, Rodriguez MA, Fayad L, Romaguera J, Pro B, Goy A, Samaniego F, Dang NH, Cabanillas F. FND (Fludarabine, Mitoxantrone, Dexamethasone)- R(Rituximab) for Patients (pt) with Relapsed (Rel) or Chemotherapy Resistant (CTR) Indolent Lymphomas (IL): A Preliminary Report. Blood 100(11), 2002. e-Pub 2002.
141. Romaguera JE, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros LJ, Pro B, Younes A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. The Clinical Significance of Detection of Gastrointestinal (GI) Involvement in Mantle Cell Lymphoma (MCL). Blood 100(11), 2002. e-Pub 2002.
142. Goy A, Sarris AH, Bleyer A, Duvic M, Mesina O, Dang NH, Fayad L, Hagemeister F, McLaughlin P, Pro B, Rodriguez MA, Romaguera J, Samaniego F, Younes A, Cabanillas F. Phase II Study of Compound GW506U78 (AraG) in Patients with T-cell and B-Cell Non-Hodgkin Lymphomas (NHL). Blood 100(11), 2002. e-Pub 2002.
143. Dang NH, Hagemeister FB, Fayad L, Pro B, McLaughlin P, Romaguera JE, Samaniego F, Younes A, Goy A, Preti A, Jones D, Sarris A, East K, Rodriguez MA, Cabanillas F. Phase II Study of Denileukin Diftitox (ONTAK) for Relapsed/Refractory B and T-cell Non-Hodgkin’s Lymphoma. Blood 100(11), 2002. e-Pub 2002.
144. A-M T, McLaughlin P, Feng L, Ayala A, Younes A, Rodriguez MA, Romaguera J, Hagemeister FB, Smith TL, Cabanillas F. Duration of Decreased Absolute Number of Circulating CD4 Cells and CD4/CD8 Ratio in Patients with Indolent Lymphoma Treated with Fludarabine. Blood 100(11), 2002. e-Pub 2002.
145. Younes A, Pro B, Hagemeister FB, Rodriguez MA, McLaughlin P, Fayad L, Goy A, Cabanillas F. Efficacy of Single Administration of a Fixed dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after Paclitaxel Plus Topotecan Chemotherapy in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma. Blood 100(11), 2002. e-Pub 2002.
146. Rodriguez MA, Sarris A, East K, Dang NH, Fayad L, Goy A, Hagemeister F, Pro B, Romaguera J, Samaniego F, Younes A, Cabanillas F. A Phase II Study of Liposomal Vincristine in CHOP with Rituximab for Elderly Patients with Untreated Aggressive B-cell Non-Hodgkin’s Lymphoma (NHL). Proceedings of the American Society of Clinical Oncology 21:1132, 2002. e-Pub 2002.
147. Wu HH, Hagemeister FB, Hess MA, McLaughlin PW, Romaguera JE, Rodriguez MA, Younes A, Manning JT, Cox JD, Muller M, Cabanillas FF. Transformation of Follicular Lymphoma: Prognostic Factors and Effect on Survival. Proceedings of the American Society of Clinical Oncology 21:1129, 2002. e-Pub 2002.
148. Hu G, Rodriguez MA, Romaguera J, McLaughlin P, Younes A, Cox J, Medeiros J, Samuels B, Cabanillas F, Hagemeister F. Pregnancy (PG) in the Patient with Lymphoma Does Not Predict an Adverse Prognosis. Proceedings of the American Society of Clinical Oncology 21:1141, 2002. e-Pub 2002.
149. Rodriguez M, Sarris A, East K, Dang N, Fayad L, Goy A, Hagemeister F, Pro B, Romaguera J, Samaniego F. A phase study of liposomal vincristine in CHOP with Rituximab for patients with untreated aggressive B-cell non-Hodgkin’s lymphoma (NHL). Int. J. Hematol 76(1):118, 2002. e-Pub 2002.
150. Younes A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F. High Response Rate and Complete Remission Rate Achieved by Adding Rituximab to Taxol Plus Topotecan (TTR) with G-CSF Support for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Lymphoma. Blood 98(11), 2001. e-Pub 2001.
151. Rodriguez MA, Dang NH, East K, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Samaniego F, Sarris A, Younes A, Cabanillas F. Melatonin Did Not Prevent CHOP-Induced Myelosuppression in Patients with Aggressive Lymphoma: Results of a Randomized Study. Blood 98(11), 2001. e-Pub 2001.
152. Cabanillas F, Ha CS, Lee MS, McLaughlin P, Rodriguez MA, Younes A, Sarris AH, Romaguera J, Pro B, Samaniego F, Cox JD. Intensive Central Lymphatic Irradiation Can Induce Systemic Molecular Responses as Measured by bcl-2 PCR Assay: Results of a Randomized Study of Radiation vs. Intensive Chemotherapy for Early Stage I-III Indolent Follicular Non-Hodgkin’s Lymphomas (NHL). Blood 98(11), 2001. e-Pub 2001.
153. Sarris AH, Visco C, Medeiros LJ, Mesina O, Rassidakis GZ, Rodriguez MA, McLaughlin P, Goy A, Hagemeister FB, Romaguera JE, Samaniego F, Dang N, Pro B, Fayad L, Ha C, Wilder R, Cox J, Cabanillas F. Non-Hodgkin’s Lymphoma Involving the Testis: Results of Treatment with CHOP, Intrathecal Methotrexate and Scrotal Radiotherapy. Blood 98(11), 2001. e-Pub 2001.
154. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Rodriguez MA, Sarris AH, Jones D, East K, Gomez R, Fayad LE, Pro B, McLaughlin P, Samaniego F, Goy A, Cabanillas F. Phase II Study of Pentostatin for Relapsed T Cell Lymphomas: Efficacy and Effect on CD26 + T Cell. Blood 98(11), 2001. e-Pub 2001.
155. McLaughlin P, Rodriguez MA, Reuben J, East K, Grimm E, Hagemeister FB, Fayad L, Sarris A. Rituximab in Combination with GM-CSF (Leukine) for Patients with Recurrent Indolent Lymphoma. Blood 98(11), 2001. e-Pub 2001.
156. Khouri IF, Saliba RM, Giralt S, Okoroji GJ, Younes A, Fayad L, Korbling M, Rodriguez MA, Couriel D, Bibawi S, Hosing C, McMannis J, Cabanillas F, Champlin RE. Long Term Remission and Low Mortality Achieved with Cisplatin, Fludarabine, Cytarabine Nonablative Preparative Regimen and Allogeneic Stem Transplantation (AST) for Histologically Aggressive Non-Hodgkins Lymphoma (NHL). Blood 98(11), 2001. e-Pub 2001.
157. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning J, Medeiros LJ, Martinez RF, Cabanillas F. Depletion of Normal B-Lymphocytes by Rituximab Therapy Alters Serum Cytokine Levels, Resolves B-Symptoms and Induces Clinical Remissions in Patients with Relapsed Classical Hodgkin’s Disease (HD). Blood 98(11), 2001. e-Pub 2001.
158. Romaguera J, Cabanillas F, Dang NH, Goy A, Hagemeister FB, Fayad L, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris AH, Younes A, Medeiros J. Mantle Cell Lymphoma (MCL) – High Rates of Complete Remission (CR) and Prolonged Failure-Free Survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without Stem Cell Transplant (SCT). Blood 98(11), 2001. e-Pub 2001.
159. Barista I, Hagemeister FB, Podoloff DA, Rodriguez MA, McLaughlin P, Romaguera JE, Ha CS, Wilder RB, Younes A, Sarris A, Cabanillas F. The Positive (POS) Gallium Scan (GA-67) in Hodgkin’s Disease (HD) at End of Therapy Predicts Freedom from Progression (FFP) and Overall Survival (OS) Results. Blood 98(11), 2001. e-Pub 2001.
160. Khouri IF, Saliba RM, Lee MS, Giralt S, Younes A, Couriel D, Fayad L, De Lima M, Hagemeister FB, Hosing C, McLaughlin P, Ueno N, Rodriguez MA, Korbling M, Gajewski J, Cabanillas F, Champlin RE. Nonablative Allogeneic Stem Cell Transplantation (AST) for Non-Hodgkin’s Lymphoma (NHL): Improved Outcome with Low Incidence of Acute GVHD and Treatment Related Mortality. Blood 98(11), 2001. e-Pub 2001.
161. Khouri IF, Saliba RM, Younes A, Acholonu S, Andersson B, Bibawi S, de Lima M, Fayad L, Giralt S, Hagemeister FB, Korbling M, Rodriguez MA, Romaguera J, Cabanillas F, Champlin RE. Allogeneic Transplantation for Poor Risk Mantle Cell Lymphoma (MCL): Chemosensitivity Predicts Superior Outcome. Blood 98(11), 2001. e-Pub 2001.
162. Younes A, Hagemeister F, Romaguera J, Dang N, Fiumara P, McLaughlin P, Rodriguez MA, Samaniego F, Khouri I, Cabanillas F. Interleukin-12 (IL-12) Decreases Serum VEGF and b-FGF Levels and Induces Clinical Remissions in Patients with Relapsed Non-Hodgkin’s Lymphoma (NHL). Blood 98(11), 2001. e-Pub 2001.
163. Pro B, Hagemeister FB, Rodriguez MA, Hess M, Romaguera J, McLaughlin P, Younes A, Sarris AH, Ha C, Cox J, Cabanillas F. Early stage primary gastric lymphoma: Excellent cure rates without surgery. Proceedings of the American Society of Clinical Oncology 20:297a, 2001. e-Pub 2001.
164. Arbuckle RB, Adamus AT, Rodriguez MA, Gillis TA, Massey PR, Lee JQ. Influence of epoetin alfa and transfusion therapy on fatigue and function in patients with lymphoma. Proceedings of the American Society of Clinical Oncology 20:305b, 2001. e-Pub 2001.
165. Khouri IF, Giralt S, Saliba R, Korbling M, Gajewski J, Younes A, Romaguera J, Anderlini P, Rodriguez MA, Donato ML, Ippoliti C, Keating M. “Mini”-Allogeneic Stem Cell Transplantation for Relapsed/Refractory Lymphomas with Aggressive Histologies. Proceedings of the American Society of Clinical Oncology 19:182, 2000. e-Pub 2000.
166. Rodriguez MA, Cabanillas F, Dang NH, Grimm EA, McLaughlin P, McAda N, Hagemeister FB, Romaguera J, Sarris A, Younes A, Richardson MA. Lymphocyte Changes in Lymphoma Patients Receiving Melatonin Plus CHOP Chemotherapy. Proceedings of the American Society of Clinical Oncology 19:72, 2000. e-Pub 2000.
167. Wood AM, Pisters K, Chi M, King KM, Arbuckle R, Rubenstein EB, Oholendt M, Rodriguez MA, Hagemeister F, Cabanillas F. Evaluation fo Antiemetic Guidelines and Outcomes in Patients Receiving Highly Emetogenic Chemotherapy Utilizing the Palm Pilot. Proceedings of the American Society of Clinical Oncology 19:2512, 2000. e-Pub 2000.
168. Anderlini P, Giralt S, Ueno N, Andersson B, Khouri I, Acholonu S, Cohen A, Manning J, Korbling M, Romaguera J, Sarris A, Rodriguez M, Hagemeister F, McLaughlin P, Cabanillas F, Champlin R. Allogeneic Stem Cell Transplantation (SCT) with Fludarabine-Based, Less Intensive Conditioning as Adoptive Immunotherapy in Advanced Hodgkin’s Disease (HD). Proceedings of the American Society of Clinical Oncology 19:240, 2000. e-Pub 2000.
169. Pericay C, Maroto P, Sola C, Montesinos J, Salazar R, Rodriguez M, Villavicencio H, Pallares C, Balmaña J, Ramirez A, Pardo B, Lopez J. Long-Term Survival in Patients (Pt) with Poor-Prognosis Germ-Cell Tumors Treated with High-Dose Chemotherapy (HDC). Proceedings of the American Society of Clinical Oncology 19:255, 2000. e-Pub 2000.
170. Sarris AH, Romaguera J, Hagemeister F, Rodriguez MA, McLaughlin P, Dang N, Tsimberidou AM, Medeiros LJ, Samuels B, Oholendt M, Mesina O, Burge C, Cabanillas F. Liposomal Vincristine: A phase II trial in relapsed of refractory non-hodgkin’s lymphomas (NHL). 7th Liposome Research days, Napa, California. Proceedings published as a monograph, 2000. e-Pub 2000.
171. Romaguera J, Dang NH, Hagemeister F, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris A, YounesA, Medeiros J, Steinbach G. Preliminary Report of Rituximab with Intensive Chemotherapy for Untreated Aggressive Mantle Cell Lymphoma (MCL). Blood 96(11):733a, 2000. e-Pub 2000.
172. Cabanillas F, McLaughlin P, Hagemeister F, Rodriguez MA, Romaguera J, Younes A, Sarris AH, Pro B, Dang N, Samaniego F, Lee MS. Molecular Responses with FND + Rituxan Chemoimmunotherapy For Stage IV Indolent Follicular Non-Hodgkin’s Lymphoma. Blood 96(11):331a, 2000. e-Pub 2000.
173. Habra MA, Thompson MA, Rodriguez MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG. Primary Natural Killer/T Cell Lymphoma of the Adrenal Gland: A Unique Presentation of a Rare Disorder. The Endocrine Society’s 87th Annual Meeting, 2000. e-Pub 2000.
174. Younes A, Romaguera J, Hagemeister F, Rodriguez MA, McLaughlin P, Medeiros J, Cabanillas F. A Pilot Study of Rituximab in Patients with Relapsed Hodgkin’s Disease of Classical Type. Blood 96(11):73a, 2000. e-Pub 2000.
175. Wilder RB, Rodriguez MA, Tucker SL, Ha CS, Hess MA, Cabanillas FF, Cox JD. Radiation Therapy’s Contribution To Local Control and Progression-Free Survival In Patients With Aggessive Lymphomas. Blood 96(11):251b, 2000. e-Pub 2000.
176. Sarris AH, Medeiros LJ, Rassidakis G, Nadali G, Viviani S, Vassilakopoulos TP, Giardini R, Chilosi M, Kittas C, Angelopoulou M, Herling M, Hagemeister FB, Rodriguez MA, Romaguera J, McLaughlin P, Ford R, Gianni M, Bonadonna G, Pangalis GA, Pizzolo G, Cabanillas F. BCL-2 Expression in Hodgkin-Reed-Sternberg Cells (HRS) of Patients (PTS) with Classical Hodgkin’s Disease (CHD) is Associated with Lower Progression-Free Survival (PFS)and Survival. Blood 96(11):725a, 2000. e-Pub 2000.
177. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Preti A, Lee MS, Cabanillas F. Randomized Comparison of Fludarabine-Novantrone-Dexamethasone (FND) Versus CHOD-BLEO /ESHAP/NOPP (Alternating Triple Therapy; ATT) In Patients with Stage IV Indolent Lymphoma. Blood 96(11):508a, 2000. e-Pub 2000.
178. Sarris AH, Hagemeister F, McLaughlin P, Rodriguez MA, Pro B, Romaguera J, Zipf T, Mesina O, Medeiros LJ, Oholendt M, Lopez-Berenstein G, Ford R, Williams T, Cabanillas F. Liposomal Tretinoin: Promising Early Results of an Ongoing Phase II Trial in Relapsed or Refractory Non-Hodgkin’s Lymphomas (NHL) and Cutaneous T-Cell Lymphomas (CTCL). 96 11(136a), 2000. e-Pub 2000.
179. Seymour JF, McLaughlin P, Fuller LM, Hagemeister FB, Hess M, Romaguera J, Rodriguez MA, Ha C, Cox J, Cabanillas F. Fifteen-Year Follow-Up of a Prospective M.D. Anderson Study of Combined-Modality Therapy For Localized Indolent Non-Hodgkin’s Lymphoma (NHL). Blood 96(11):509a, 2000. e-Pub 2000.
180. Romaguera J, Dang N, Hagemeister F, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris A, Younes A, Cabanillas F. Evidence For Need of Upper and Lower Endoscopies With Biopsy In Staging of Asymptomatic Patients With Aggressive Mantle Cell Lymphoma (MDL). 96 11(334a), 2000. e-Pub 2000.
181. Schlembach PJ, Wilder RB, Tucker SL, Ha CS, Hess MA, Rodriguez MA, Cabanillas FF, Cox JD. Involved field radiotherapy after chop-based chemotherapy improves local control and freedom from progression in patients with bulky, clinical stage III-IV, intermediate grade of large-cell immunoblastic lymphomas. Proceedings of the 42nd Annual ASTRO Meeting, International Journal of Radiation Oncology Biology Physics 48(No. 3, Suppl), 2000. e-Pub 2000.
182. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Pate O, Tsimberidou MA, Medeiros LJ, Burge C, Kantarjian H, Cabanillas F. Liposomal Vinctristine in relapsed NHL: early results. Ann. Oncol 10(Suppl. 3):35, 1999. e-Pub 1999.
183. Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin PW, Sarris AH, Younes A, Rodriguez J, Pate O, Keating MJ, Koller CA, Riggs SA, Champlin R, Cabanillas F. Untreated aggressive mantle cell lymphoma (MCL) presents with frequent gastrointestinal involvement and has high complete response (CR) rates with intensive chemotherapy (IC) without stem cell transplant. Ann. Oncol 10(Suppl. 3):57, 1999. e-Pub 1999.
184. Sarris AH, Duvic M, Romaguera J, Rodriguez MA, Medeiros LJ, Pate O, Cabanillas. Trimetrexate in relapsed cutaneous T-cell Lymphoma. Ann. Oncol 10(Suppl. 3):142, 1999. e-Pub 1999.
185. Sarris AH, Duvic M, Romaguera J, Rodriguez MA, Medeiros LJ, Pate O, Cabanillas F. Phase II Trial of Trimetrexate (TMTX) in Relapsed Cutaneous T-Cell Lymphoma (CTCL). Proceedings of ASCO Volume 18:133, 1999. e-Pub 1999.
186. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival (FFS) in indolent Follicular Lymphoma. Ann. Oncol 10(Suppl. 3):24, 1999. e-Pub 1999.
187. Fayad L, Rodriguez MA, Rodriguez J, Hagemeister F, Younes A, Sarris A, Romaguera J, McLaughlin P, Cabanillas F. Gallium (67Ga) Scan Result After Second or More Cycles of Chemotherapy Correlates with Clinical Outcome in Aggressive Good Prognosis NHL (AGPNHL) Treated with CHOP Containing Regimen. Proceedings of ASCO Volume 18:58, 1999. e-Pub 1999.
188. Cabanillas F, Lopez-Guillermo A, McLaughlin P, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS. Clinical significance of a Molecular relapse in patients with follicular Lymphoma (FL) who achieve a molecular response. Forty-First Annual Meeting of the American Society of Hematology 94(10, Supplement 1):2663, 1999. e-Pub 1999.
189. Pro B, Hagemeister FB, Rodriguez MA, Romaguera J, McLaughlin P, Cox J, Cabanillas F. Primary large cell gastric lymphoma. Ann. Oncol 10(Suppl. 3):143, 1999. e-Pub 1999.
190. Herling M, Medeiros LJ, Kliche KO, Khorana S, Mesina O, Rodriguez MA, Cabanillas, Sarris AH. Expression of the EBV-Coded latent membrane protein-1 (LMP-1) in hodgkin-reed-sternberg cells is associated with inferior progression-free survival in hodgkin’s disease. Oncology 22(Suppl. 1):476a, 1999. e-Pub 1999.
191. Sarris AH, Medeiros LJ, Khorana S, Herling M, Viviani S, Bonfante V, Giardini R, Hagemeister FB, Romaguera J, McLaughlin P, Preti A, Rodriguez MA, Notti P, Ford R, Bonadonna G, Cabanilla F. BCL-2 is frequently expressed in Hodgkin-Reed-Sternberg Cells and is associated with inferior failure-free survival in Hodgkin’s disease treated with ABVD. Ann. Oncol 10(Suppl. 3):72, 1999. e-Pub 1999.
192. Sarris AH, Kliche KO, Peethambaram PP, Preti A, Jackow C, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Duvic M, Witzig T, Andreeff M, Cabanillas F. Serum Interleukin-10 (IL-10) and failure-free survival (FFS) of adult Hodgkin’s disease (HD). The Fourth International Symposium on Hodgkin’s Lymphoma. Köln, Germany. Leuk. Lymph 29(suppl 1):32, 1998. e-Pub 1998.
193. Sarris AH, Viviani S, Bonfante V, Kliche KO, Notti P, Peethambaram P, Tucker S, Preti A, Mesina O, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Andreef M, Witzig T, Bonadonna J, Cabanillas F. A prognostic model for Hodgkin’s Disease (HD) based on IL-10. Fortieth Annual Meeting of the American Society of Hematology:991, 1998. e-Pub 1998.
194. Khouri I, Mirza N, Rodriguez MA, Przepiorka D, McLaughlin P, Younes A, Giralt S, Korbling M, Donato M, Gajewski J, Cabanillas F, Champlin R. Superiority of allogeneic (ALLO-BMT) to autologous (ABMT) marrow or blood stem cell transplantation for low grade lymphoma (LGL). Fortieth Annual Meeting of the American Society of Hematology:1177, 1998. e-Pub 1998.
195. Cabanillas F, Lee MS, McLaughlin P, Cox J, Hagemeister FB, Ha C, Rodriguez MA, Romaguera J, Sarris A, Younes A. Detection of minimal residual disease by bcl-2 PCR in early stage follicular lymphomas (FL). Fortieth Annual Meeting of the American Society of Hematology:1297, 1998. e-Pub 1998.
196. Rodriguez J, Tucker S, Romaguera J, McLaughlin P, Hagemeister F, Rodriguez MA, Cabanilla F. Treatment outcome in patients >70 years old with diffuse large cell lymphoma (DLCL). Fortieth Annual Meeting of the American Society of Hematology:4027, 1998. e-Pub 1998.
197. Strom SS, Gu Y, Tee PG, Rodriguez MA. Familial aggregation of Hodgkin’s disease. Am J Human Genetics, Program and Abstracts Annual Meeting:478, 1998. e-Pub 1998.
198. Rodriguez J, Tucker J, Romaguera J, McLaughlin P, Hagemeister F, Rodriguez MA, Cabanillas F. Patients 60-69 years old with diffuse large cell lymphoma (DLCL) constitute a unique and heterogeneous prognostic category. Fortieth Annual Meeting of the American Society of Hematology:2568, 1998. e-Pub 1998.
199. Sarris AH, Medeiros LJ, Herling, Khorana S, Kliche KO, Mesina O, Hagemeister FB, Romaguera J, McLaughlin P, Preti HA, Rodriguez MA, Andreeff M, Cabanillas F. The expression of the EBV-Coded latent membrane protein-1 (LMP-1) in Reed-Sternberg cells of Hodgkin’s Disease (HD) is associated with higher serum-IL-10 levels and inferior failure-free survial (FFS). Fortieth Annual Meeting of the American Society of Hematology:353, 1998. e-Pub 1998.
200. Anderlini P, Andersson B, Gajewski J, Giralt S, Mehra R, Sarris A, Claxton D, Ueno N, McLaughlin P, Khouri I, Hagemeister F, Przepiorka D, Younes A, Donato M, Romaguera J, Rodriguez M, Korbling M, Cabanillas F, Champlin R. Allogeneic stem cell transplantation for advanced Hodgkin’s Disease: The M.D. Anderson Experience. Proceedings of the American Society of Clinical Oncology:338, 1998. e-Pub 1998.
201. Rodriguez J, McLaughlin P, Fayad L, Hagemeister F, Santiago M, Rodriguez MA, Romaguera J, Cabanillas F. Follicular large cell lymphoma 15-year follow-up on 62 patients. Proceedings of the American Society of Clinical Oncology:36, 1998. e-Pub 1998.
202. Popat U, Andersson BS, Smith T, Amin K, Hughes P, Fahmi H, Giralt S, Mehra R, Przepiorka D, vanBesien K, Khouri I, Gajewski J, Claxton D, Rodriguez M, Romaguera J, Hagemeister F, Cabanillas F, Champlin RE. Second malignancies after high dose therapy for Hodgkin’s disease (HD). Proceedings of the American Society of Clinical Oncology:334, 1998. e-Pub 1998.
203. Rodriguez MA, Swan F, Hagemeister F, Hess M, McLaughlin P, Romaguera J, Sarris A, Younes A, Cabanillas FC. Tumor score system (TSS) selects a highly favorable subset of patients (PTS) with large cell lymphoma. Proceedings of the American Society of Clinical Oncology:137, 1998. e-Pub 1998.
204. Fayad L, McLaughlin P, Fuller L, Hagemeister F, Rodriguez M, Romaguera J, Cox J, Cabanillas F. Stage III follicular lymphoma: Durable remissions with a combined chemotherapy-radiotherapy regimen: Long-term follow-up of 110 patients. Proceedings of the American Society of Clinical Oncology:37, 1998. e-Pub 1998.
205. Sarris AH, Kliche KO, Preti A, Jackow C, Smith T, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Pugh W, Fritsche H, Duvic M, Andreef M, Cabanillas F. Pretreatment Serum Interleukin-10 is a prognostic factor for failure-free survival of adults with Hodgkin’s disease: Implications for Therapy. Pan-Pacific Lymphoma Conference. Island of Lanai, Hawaii, 1997. e-Pub 1997.
206. Rodriguez J, Rodriguez MA, Fayad L, Hagemeister FB, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F. ASAP is an effective salvage regimen in patients with refractory or recurrent Hodgkin’s disease. Thirty-Ninth Annual Meeting of the American Society of Hematology:1518, 1997. e-Pub 1997.
207. Romaguera J, Khouri I, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris A, Younes A, Keating MJ, Koller C, O’Brien S, Riggs S, Kantarjian H, Champlin R, Cabanillas F. HCVAD/ARA-C-MTX (HCVAD/A-M) with or without high dose chemotherapy and stem cell transfusion (SCT) as salvage for relapsed or refractory diffuse/nodular mantle cell lymphoma (MCL). Thirty-Ninth Annual Meeting of the American Society of Hematology:834, 1997. e-Pub 1997.
208. Rodriguez J, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Cabanillas F, McLaughlin P. Follicular large cell lymphoma (FLCL) long-term results at M.D. Anderson Cancer Center. Thirty-Ninth Annual Meeting of the American Society of Hematology:839, 1997. e-Pub 1997.
209. Cabanillas F, Romaguera J, Hagemeister FB, Younes A, McLaughlin P, Sarris A, Rodriguez MA. Randomized study of idarubicin (IDA) vs adriamycin (Adria)-based combination chemotherapy for aggessive poor prognosis (tumor score >3) non-Hodgkin’s lymphomas (APPNHL). Thirty-Ninth Annual Meeting of the American Society of Hematology:1093, 1997. e-Pub 1997.
210. Sarris AH, Preti A, Smith T, Mesina O, Santiago M, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Riggs S, Ha C, Pugh W, McBride A, Cox J, Cabanillas F. A predictive model for failure-free survival (FFS) of adults with Hodgkin’s disease (HD) treated with AVBD or equivalent regimens. Thirty-Ninth Annual Meeting of the American Society of Hematology:1727, 1997. e-Pub 1997.
211. Popat U, Andersson BS, van Besien K, Smith T, Amin K, Hughes P, Fahmi H, Giralt S, Mehra R, Przepiorka D, Khouri I, Gajewski J, Claxton D, Rodriguez M, Romaguera J, Hagemeister F, Cabanillas F, Champlin RE. ABMT in recurrent or refractory HD: Long term results. Thirty-Ninth Annual Meeting of the American Society of Hematology:500, 1997. e-Pub 1997.
212. Sarris AH, Santiago M, Preti A, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Riggs S, Ha C, McBride A, Pugh W, Cox J, Cabanillas F. The number of involved sites (NIS) predicts failure-free survival (FFS) for adults with Hodgkin’s disease (HD) treated with ABVD or equivalent regimens. Thirty-Ninth Annual Meeting of the American Society of Hematology:3954, 1997. e-Pub 1997.
213. Romaguera J, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Phase II study of Taxol in combination with Mitoxantrone and Ifosfamide (MINT) with consolidation ESHAP for lymphomas. Thirty-Ninth Annual Meeting of the American Society of Hematology:835, 1997. e-Pub 1997.
214. Rodriguez J, Romaguera J, McLaughlin P, Hagemeister F, Rodriguez M, Cabanillas F. Dose intensity as a treatment related variable in aggressive non-Hodgkin’s lymphoma. Thirty-Ninth Annual Meeting of the American Society of Hematology:3946, 1997. e-Pub 1997.
215. Sarris AH, Kliche KO, Smith T, Mesina O, Preti A, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Pugh W, Fuller L, Ha C, Cox J, Andreeff M, Cabanillas F. Hodgkin’s Disease: Prognostic factors, including IL-10: A model for pathogenesis and a guide to therapy. Intl. J. Oncol 11:913, 1997. e-Pub 1997.
216. Fayad L, Podoloff D, Rodriguez J, Hagemeister F, Younes A, Sarris A, Rodriguez MA, Romaguera J, McLaughlin P, Cabanillas F. Gallium (67Ga) Scan result after second course of chemotherapy correlates with clinical outcome in aggressive poor prognosis non-Hodgkin’s lymphomas (APPNHL) treated with alternating triple therapy regimen (ATT). Thirty-Ninth Annual Meeting of the American Society of Hematology:836, 1997. e-Pub 1997.
217. Sarris AH, Daliani D, Mesina O, Hagemeister FB, McLaughlin P, Preti A, Romaguera J, Rodriguez MA, Pugh W, Fuller L, Ha C, Cox J, Cabanillas F. A prognositc model for failure-free survival (FFS) of adults with clinical Ann Arbor stage (AAS) I or II Hodgkin’s disease (HD) after combined modality therapy. Proceedings of the American Society of Clinical Oncology:23, 1997. e-Pub 1997.
218. Rodriguez J, Hagemeister FB, Rodriguez MA, McLaughlin P, Cabanillas. Prognostic factors in elderly patients with aggressive lymphoma. Proceedings of the American Society of Clinical Oncology:72, 1997. e-Pub 1997.
219. Younes A, Preti A, Romaguera J, North L, Mesina O, Hagemeister F, Sarris A, McLaughlin P, Rodriguez MA, Cabanillas F. Activity of Taxol and high-dose Cytoxan with granulocyte coloney-stimulating factor (G-CSF) in 54 patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL). Proceedings of the American Society of Clinical Oncology:74, 1997. e-Pub 1997.
220. Sarris AH, Papadimitrakopoulou V, Dimopoulos MA, Braunschweig I, Smith T, Pugh W, Rodriguez MA, Ha C, Callender D, Cox J, McLaughlin P, Cabanillas F. Primary parotid lymphoma: the effect of International Prognositc Index on outcome. Proceedings of the American Society of Clinical Oncology:65, 1997. e-Pub 1997.
221. Braunschweig I, Smith T, Pugh W, Rodriguez MA, Ha C, Callender D, Cox J, McLaughlin P, Cabanillas F. Primary paratoid lymphoma: the effect of International Prognostic Index on outcome. Proceedings of the American Society of Clinical Oncology:65, 1997. e-Pub 1997.
222. Van Besien K, Rodriguez M, Amin K, Mehra R, Romaguera J, Giralt S, McLaughlin P, Andersson B, Hagemeister F, Gajewski J, Sarris A, Przepiorka D, Miizra N, Younes A, Preti A, Bachier C, Champlin R, Cabanillas F. Intensive reinduction with high-dose ifosfamide/VP-16 and ifosfamide/novantrone followed by BEAM and stem cell transplant for recurrent lymphoma (NHL). Proceedings of the American Society of Clinical Oncology:73, 1997. e-Pub 1997.
223. McLaughlin P, Cabanillas F, Younes A, Lee MS, Rodriguez MA Hagemeister FB, Sarris A, Preti A. Stave IV Low Grade Lymphoma (LGL): Randomized Trial of Two Innovative Regimens, with Monitoring of BCL-2 by PCR. Sixth International Conference on Malignant Lymphoma, Lugano:109, 1996. e-Pub 1996.
224. Romaguera JE, Diaz-Pavon R, Carias L, Hagemeister FB, McLaughlin P, Rodriguez MA, Sarris AH, Younes A, Preti A, Llerena E, Cabanillas F. Use of the International Prognostic Index (IPI) and The Tumor Score (TS) to Detect Poor-Risk Patients with Primary Mediastinal Large B-cell Lymphoma (PMLCL): A Study with 37 Previously Untreated Patients. Sixth International Conference on Malignant Lymphoma:565, 1996. e-Pub 1996.
225. McLaughlin P, Hess M, Hagemeister FB, Romaguera JE, Rodriguez MA, Cabanillas F. Long-Term Follow-Up of CHOP-BLEO Plus Interferon for Stage IV Low Grade Lymphoma. Sixth International Conference on Malignant Lymphoma Lugano:543, 1996. e-Pub 1996.
226. Younes A, Ayoub JP, Sarris A, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Preti A, Bachier C, Cabanillas F. Paclitaxel (Taxol): An Active New Drug for the Treatment of Non-Hodgkin's Lymphoma (NHL). Sixth International Conference on Malignant Lymphoma, Lugano:103, 1996. e-Pub 1996.
227. Melnyk A, Rodriguez MA, Pugh WC, Cabanillas F. Evaluation of the R.E.A.L. Classifiction Confirms the Clinical Relevance of Immunophenotype in 560 Cases of Aggressive Non-Hodgkin's Lymphoma (NHL). Proceedings of the American Society of Clinical Oncology:1262, 1996. e-Pub 1996.
228. Younes A, Romaguera J, Sarris A, North L, Preti A, Hagemeister F, McLaughlin P, Rodriguez MA, Cabanillas F. Phase II Trial of Infusional Taxol and High Dose Cytoxan wit Granulocyte Colony Stimulating Factor (Filgrastim) for the Treatment of Relapsed/Refractory Intermediate Grade Non-Hodgkin's Lymphoma (NHL). Proceedings of the American Society of Clinical Oncology:1258, 1996. e-Pub 1996.
229. Palos GR, Gilmore KR, Chapman P, Bi W, Lewis-Patterson P, Rodriguez MA. Patterns of Providers' Mammagram Referrals for Asymptomatic Breast Cancer Survivors. National Comprehensive Cancer Network (NCCN) Improving the Quality, Effectiveness, and Efficiency of Cancer Care™.
230. Rodriguez MA. Clinical algorithms to manage symptoms and late effects of cancer in long-term survivors. 2014 Palliative Care Oncology Symposium.
231. Ferrajoli A, DeJesus Y, Cheng L, Rodriguez MA. Incidence rate of venous thromboembolism (VTE) and utilization of a VTE prophylaxis orderset module in hospitalization patients with leukemia.
232. Palos GR, Zandstra F, Russell L, Gilmore K, Flores J, Ozeri D, Leong C, Nguyen D, Patel M, Rodriguez MA. Planning Cancer Wellness Survivorship Programs for Community-Based Adult Survivors. Cancer.
233. Zandstra F, Palos GR, Russill L, Bi W, Ozeri D, Gilmore K, Rodriguez MA. Auditing Clinicians' Concordance with Practice Algorithms Tailored for Adult Survivors of Diffuse Large B-Cell Lymphoma and Hodgkin's Lymphoma. Cancer.

Book Chapters

1. Rodriguez, MA, Gallagher, CM. Ethics in Cancer Care Delivery—Do Not Resuscitate, 581-588, 2023.
2. Sullivan, TJ, Whitehead, K, Williamson, R, Grimes, D, Schlect, D, Brown, I, Dickie, G, Bhatia, S, Paulino, AC, Buatti, JM, Mayr, NA, Wen, BC, Pinnix, CC, Dabaja, BS, Milgrom, SA, Smith, GL, Abou, Z, Nastoupil, L, Romaguera, JE, Turturro, F, Fowler, N, Fayad, LE, Westin, JR, Neelapu, SS, Fanale, MA, Rodriguez, MA, Hagemeister, FB, Lee, HJ, Oki, Y, Wang, L, Samaniego, F, Chi, L, Esmaeli, B. Orbital adnexal lymphoma, 375-388, 2022.
3. Rodriguez MA, Lewis-Patterson P. Chapter 1: General Principles. In: Handbook of Cancer Survivorship Care. Demos Medical Publishing, 2018.
4. Rodriguez MA, Mullen E, Mistry H. Chapter 14: Lymphoma Survivorship Care. In: Handbook of Cancer Survivorship Care. Demos Medical Publishing, 2018.
5. Rodriguez MA, Lewis-Patterson P, Palos G. Chapter 5: Ethical Issues in Cancer Survivorship. In: Ethical Challenges in Oncology. Academic Press, An Imprint of Elsevier, 85-98, 2017.
6. Ratan R, Ater J, Rieber A, Rodriguez MA. Long-Term Survivorship in Adult and Pediatric Cancer. In: The MD Anderson Manual of Medical Oncology, Third Edition. 3rd. McGraw-Hill Education, 1211, 2016.
7. Rodriguez MA, Ballas L, and Simar K. Hematologic Cancer Survivorship Management: Lymphoma. In: Advances in Cancer Survviorship. 1st. Springer, 201-218, 2014.
8. Rodriguez MA, Zandstra F. Models of Survivorship Care. In: Advances in Cancer Survivorship. 1st. Springer, 7-25, 2014.
9. Rodriguez MA. Introduction. In: Advances in Cancer Survivorship. 1st. Springer, 1-4, 2014.
10. Rodriguez MA. Introduction. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, 1-3, 2012.
11. Rodriguez MA. Non-Hodgkin Aggressive B-Cell Lymphoma. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, 251-262, 2012.
12. Fayad L, Konoplev S, Chuang H, Rodriguez MA, Commentary: Dabaja BS. Aggressive and Highly Aggressive B-Cell Lymphomas. In: The MD Anderson Manual of Medical Oncology. 2. McGraw-Hill, 147-182, 2011.
13. Holm MJ, Selvan M, Smith ML, Markman M, theriault R, Rodriguez MA, Martin S. Quality Improvement or Research: Defining and Supervising Q1 at the University of Texas M. D. Anderson Cancer Center. In: Health Care Quality Improvement: Ethical and Regulatory Issues. The Hastings Center, 2007.
14. Rodriguez MA, Sneed T, Kantarjian HM, Wolff RA, Koller CA. Aggressive and Highly Aggressive Lymphomas. In: M.D. Anderson Manual of Medical Oncology. McGraw-Hill Publishers, 101-140, 2006.
15. Rodriguez MA Bseiso AW. Lymphomas of the Head and Neck: Chapter 34. In: Head and Neck Cancer: A Multidisciplinary Approach. Lippincott-Raven Publishers, 2004.
16. Rodriguez MA Cabanillas F. Prognostic Factors in Non-Hodgkin’s Lymphoma. BC Decker Inc. Publisher, 2001.
17. Pro B Rodriguez A. Gastric Cancer in the MD Anderson Solid Tumor Oncology Series. In: Management of Primary Gastric Lymphoma. Springer-Verlag, 1999.
18. Rodriguez MA Pugh W. Mantle Cell Lymphomas: Chaper 4. In: Advances in Lymphoma Research. Kluwer Academic Publishers, 1996.
19. Rodriguez MA, Cabanillas FC, Deisseroth AB. Non-Hodgkin's lymphoma. In: Hematology: A Problem-Solving Approach. Lea & Febringer, 1996.
20. Rodriguez MA Hong WK. Diagnosis and Management of Lymphomas in the Head and Neck: Chapter 32. In: Cancer of the Head and Neck. W.B. Saunders, 1996.
21. Melnyk A Rodriguez MA. Intermediate and High Grade non-Hodgkin's Lymphomas. In: Chapter 6 Medical Oncology: A Comprehensive Review. PRR, 1996.
22. Rodriguez MA. Factors That Influence Prognosis of Intermediate Grade Lymphomas At Relapse: Chapter 6. In: Advances in Lymphoma Research. Kluwer Academic Publishers, 1996.
23. Rodriguez MA, Romaguera JE, Swan F, Cabanillas FC, McLaughlin P. Prognostic variables in low-grade lymphomas. In: Autologous Bone Marrow Transplantation for Hodgkin's Disease, Non-Hodgkin's Lymphoma and Multiple Myeloma. Springer-Verlag, 1993.
24. Rodriguez MA Hong WK. Lymphomas presenting in the head and neck: Current issues in diagnosis and management. In: Advances in Otolaryngology -Head and Neck Surgery. Mosby Yearbook, 1991.
25. Rodriguez MA Cabanillas F. Linfomas de linfocitos T perifericos y otras entidades relacionadas. In: Chapter 6, in Linfomas. Editorial Doyma, 1988.
26. Rodriguez MA Cabanillas F. Evaluacion y manejo de los linfomas de alto grado. In: Chapter 7, in Linfomas. Editorial Doyma, 1988.
27. Rodriguez MA Meyskens FL. Chemosensitivity testing techniques applied to human melanoma. In: Contemporary Issues In Clinical Oncology - Management Of Advanced Melanoma. Churchill Livingstone, 91-99, 1986.

Books (edited and written)

1. Rodriguez MA, Foxhall L. Handbook of Cancer Survivorship Care, 2018.
2. Foxhall L, Rodriguez MA. Advances in Cancer Survivorship Management. Ed(s) 1ed. Springer, 2014.
3. Rodriguez MA, Walters RS, Burke TW, Eds. 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, 2012.
4. Cabanillas FC Rodriguez MA. Advances in Lymphoma Research. Kluwer Academic Publishers, 1996.

Letters to the Editor

1. Seymour JF, Rodriguez, MA. Comments on "mental neuropathy (numb chin syndrome): a harbinger of tumor progression or relapse". Cancer 71: 874-875, 1993.